var title_f11_2_11296="Central airway obstruction";
var content_f11_2_11296=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/64313/centairwayfbe_conv.mp4?title=Central+airway+obstruction\" style=\"width:320px;height:236px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Central airway obstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Caused by aspiration of a large piece of meat. Foreign body forceps are used for extraction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles Marquette, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_2_11296=[""].join("\n");
var outline_f11_2_11296=null;
var title_f11_2_11297="Amorolfine: International drug information";
var content_f11_2_11297=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"23\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amorolfine: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F1977711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Loceryl (AT, AU, BE, BR, CH, CZ, DE, DK, FI, FR, GB, HR, HU, IE, LU, MX, NO, SE);",
"     </li>",
"     <li>",
"      Locetar (AR, ES, IT);",
"     </li>",
"     <li>",
"      Odenil (ES);",
"     </li>",
"     <li>",
"      Pekiron (JP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1977696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Amorolfine Hydrochloride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1977703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antifungal Agent, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1977706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical treatment of nail infections caused by a variety of fungi (onychomycosis)",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1977699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Apply to affected toenails or fingernails once or twice weekly. Treatment may be needed for &sim;6 months for fingernails or 9-12 months for toenails.",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1977705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Liquid, topical, as hydrochloride: 250 mg/5 mL (5 mL) [packaged with 10 spatulas, 30 cleaning pads, and 30 nail files]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10527 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-6DBE490E2D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_2_11297=[""].join("\n");
var outline_f11_2_11297=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977711\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977696\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977703\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977706\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977699\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821209\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977705\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10527\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10527|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_2_11298="Gram positive cocci clusters 1";
var content_f11_2_11298=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    in wound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram positive cocci in clusters under high power magnification (1000x) from a knee aspirate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_2_11298=[""].join("\n");
var outline_f11_2_11298=null;
var title_f11_2_11299="Wt length girls z 0 2";
var content_f11_2_11299=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 625px\">",
"   <div class=\"ttl\">",
"    Weight-for-length girls: birth to 2 years (z-scores)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 605px; height: 387px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The WHO Child Growth Standards. World Health Organization, Geneva, 2008. Available at file://www.who.int/childgrowth/standards/en/. Copyright &copy;2008 World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_2_11299=[""].join("\n");
var outline_f11_2_11299=null;
var title_f11_2_11300="Pemphigus foliaceus scalp";
var content_f11_2_11300=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60530&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60530&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pemphigus foliaceus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The scalp and periauricular lesions resemble those of seborrheic dermatitis in this patient with pemphigus foliaceus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_2_11300=[""].join("\n");
var outline_f11_2_11300=null;
var title_f11_2_11301="Classification of sleep disorders";
var content_f11_2_11301=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Classification of sleep disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/2/11301/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/2/11301/contributors\">",
"     Brooke G Judd, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/2/11301/contributors\">",
"     Michael J Sateia, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/2/11301/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/2/11301/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/2/11301/contributors\">",
"     Ruth Benca, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/2/11301/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/2/11301/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/2/11301/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic classification of sleep disorders is important because it standardizes definitions, improves awareness of the conditions, promotes a broad differential diagnosis, and facilitates a systematic diagnostic approach. The following are discussed in this topic review:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 2nd edition of the International Classification of Sleep Disorders (ICSD-2) and its impact on alternative classification systems.",
"     </li>",
"     <li>",
"      The eight major categories of the ICSD-2 system and the sleep disorders included within each.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many of the sleep disorders are described in greater detail separately, including insomnia, obstructive sleep apnea, central sleep apnea syndrome, Cheyne-Stokes breathing, narcolepsy, and restless legs syndrome. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ICSD-2 SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2nd edition of the International Classification of Sleep Disorders (ICSD-2) was published by the American Academy of Sleep Medicine in 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11301/abstract/1\">",
"     1",
"    </a>",
"    ]. This system classifies sleep disorders into eight major categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Insomnia",
"     </li>",
"     <li>",
"      Sleep related breathing disorders",
"     </li>",
"     <li>",
"      Hypersomnias of central origin",
"     </li>",
"     <li>",
"      Circadian rhythm sleep disorders",
"     </li>",
"     <li>",
"      Parasomnias",
"     </li>",
"     <li>",
"      Sleep related movement disorders",
"     </li>",
"     <li>",
"      Isolated symptoms and normal variants",
"     </li>",
"     <li>",
"      Other sleep disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ICSD-2 includes over 70 specific diagnoses within the eight major categories, as well as two appendices for classification of sleep disorders associated with medical or psychiatric disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Impact on other classification systems",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impact on ICD-9-CM &ndash; Classification of sleep disorders within the current International Classification of Diseases (ICD-9-CM) was revised at the same time that ICSD-2 was published, in order to establish greater concordance between the systems. Many sleep disorders are now grouped into a single new series within the \"Diseases of the Nervous System\" section of ICD-9-CM, although some remain in other sections of ICD-9-CM (especially the \"Mental Disorders\" section).",
"     </li>",
"     <li>",
"      Impact on DSM-IV &ndash; The 4th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) of the American Psychiatric Association (APA) also classifies sleep disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?11/2/11301/abstract/2\">",
"       2",
"      </a>",
"      ]. Publication of ICSD-2 and the associated ICD changes have made a number of DSM-IV sleep codes obsolete. The APA refers clinicians to the new ICD-9-CM codes. This discrepancy will likely be addressed with the publication of DSM-V.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INSOMNIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The insomnia category includes conditions that are characterized by difficulty initiating or maintaining sleep, or by poor quality sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11301/abstract/1\">",
"     1",
"    </a>",
"    ]. The classification of insomnia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4758?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of insomnia\", section on 'Types of insomnia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SLEEP RELATED BREATHING DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep related breathing disorders are characterized by abnormal respiration during sleep; they occur in both adults and children [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11301/abstract/1\">",
"     1",
"    </a>",
"    ]. There are three major sleep related breathing disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Central sleep apnea syndromes",
"     </li>",
"     <li>",
"      Obstructive sleep apnea syndromes",
"     </li>",
"     <li>",
"      Sleep related",
"      <span class=\"nowrap\">",
"       hypoventilation/hypoxemia",
"      </span>",
"      syndromes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These syndromes are further divided according to their etiology:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The central sleep apnea syndromes include primary central sleep apnea, central sleep apnea due to Cheyne-Stokes breathing, central sleep apnea due to high altitude periodic breathing, central sleep apnea due to a medical condition, central sleep apnea due to drug, medication, or substance use, and primary sleep apnea of infancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44502?source=see_link\">",
"       \"Central sleep apnea: Risk factors, clinical presentation, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39239?source=see_link\">",
"       \"Central sleep apnea: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The obstructive sleep apnea syndromes include adult obstructive sleep apnea and pediatric obstructive sleep apnea. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=see_link\">",
"       \"Overview of obstructive sleep apnea in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The sleep related",
"      <span class=\"nowrap\">",
"       hypoventilation/hypoxemia",
"      </span>",
"      syndromes include idiopathic sleep related nonobstructive alveolar hypoventilation, congenital central alveolar hypoventilation syndrome, and sleep related",
"      <span class=\"nowrap\">",
"       hypoventilation/hypoxemia",
"      </span>",
"      due to a medical condition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pulmonary disorders (eg, chronic obstructive pulmonary disease, asthma) are not considered sleep related breathing disorders themselves; however, they can cause or exacerbate abnormal breathing (eg, hypoventilation, hypoxemia) during sleep. In this context, the diagnosis of sleep related",
"    <span class=\"nowrap\">",
"     hypoventilation/hypoxemia",
"    </span>",
"    is indicated. Sleep-related laryngospasm and sleep choking syndrome are also not considered sleep related breathing disorders; instead, they are considered medical disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HYPERSOMNIA OF CENTRAL ORIGIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypersomnia of central origin category includes those disorders in which the primary complaint is daytime sleepiness that is not due to disturbed sleep or misaligned circadian rhythms [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11301/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major diagnoses within this category are narcolepsy (with or without cataplexy) and idiopathic hypersomnia (with or without long sleep time). Behaviorally-induced insufficient sleep (ie, voluntary sleep deprivation) is also included in this category. Other sleep disorders can give rise to excessive sleep and must be properly treated before hypersomnia of central origin can be diagnosed.",
"   </p>",
"   <p>",
"    Narcolepsy and sleep deprivation are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25913?source=see_link\">",
"     \"Clinical features and diagnosis of narcolepsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/62/4071?source=see_link\">",
"     \"Treatment of narcolepsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4487?source=see_link\">",
"     \"Definition and consequences of sleep deprivation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CIRCADIAN RHYTHM SLEEP DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circadian rhythm disorders are characterized by chronic or recurrent sleep disturbance due to misalignment between the environment and an individual's sleep-wake cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11301/abstract/1\">",
"     1",
"    </a>",
"    ]. There are several types of circadian rhythm disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Shift work sleep disorder and jet lag disorder are the most common types of circadian rhythm sleep disturbances, although these do not often come to medical attention. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35861?source=see_link\">",
"       \"Jet lag\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/51/38710?source=see_link&amp;anchor=H6#H6\">",
"       \"Performance and safety risks of sleep deprivation and sleep disorders\", section on 'Circadian rhythm sleep disorders'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Delayed sleep phase disorder is characterized by sleep and wake times that are habitually delayed compared to conventional times. Sleep is usually normal once it is initiated. A typical patient has difficulty falling asleep and awakens late. This disorder is more prevalent in younger patients.",
"     </li>",
"     <li>",
"      Advanced sleep phase disorder is characterized by sleep and wake times that are habitually early compared to conventional time. A typical patient falls asleep early and awakens early spontaneously. This disorder is not commonly reported, but it is more likely to be observed in the elderly.",
"     </li>",
"     <li>",
"      Circadian rhythm disorders can also be due to a medical condition. As an example, blind persons without photoreception often lack a normal 24-hour cycle of sleep and wake propensity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PARASOMNIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parasomnias are undesirable physical events (movements, behaviors) or experiences (emotions, perceptions, dreams) that occur during entry into sleep, within sleep, or during arousals from sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11301/abstract/1\">",
"     1",
"    </a>",
"    ]. The behaviors can be complex and appear purposeful; however, the patient has no conscious awareness of the behavior. The parasomnia category can be divided:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Non-rapid eye movement (NREM) related parasomnias are disorders of arousal. They include confusional arousals, sleepwalking, and sleep terrors.",
"     </li>",
"     <li>",
"      Rapid eye movement (REM) related parasomnias involve the intrusion of the features of REM sleep into wakefulness (eg, sleep paralysis), exaggeration of the features of REM sleep (eg, nightmare disorder), or failure to manifest one of the core features of REM sleep (eg, lack of atonia as observed in REM sleep behavior disorder).",
"     </li>",
"     <li>",
"      Miscellaneous parasomnias are parasomnias that bear no specific relationship to sleep stage, such as nocturnal enuresis or sleep-related hallucinations. These include parasomnias associated with medical disorders, or drug, medication, or substance use.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SLEEP RELATED MOVEMENT DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep related movement disorders are characterized by simple, stereotypic movements that disturb sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11301/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients may or may not be aware of the movements. Symptoms of sleep disturbance (eg, daytime sleepiness, fatigue) are required to diagnose a sleep related movement disorder. Movements that occur during sleep but do not adversely affect sleep or daytime function are not considered a sleep related movement disorder.",
"   </p>",
"   <p>",
"    Classic sleep related movement disorders include restless legs syndrome, periodic limb movement disorder, sleep related bruxism (teeth grinding), and sleep related rhythmic movement disorder. Restless legs syndrome is categorized as a sleep related movement disorder due to its close association with periodic limb movement and its temporal relationship to sleep onset, even though it does not primarily manifest as simple, stereotypic movements. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=see_link\">",
"     \"Restless legs syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ISOLATED SYMPTOMS AND NORMAL VARIANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;This category includes sleep related symptoms or events that do not meet the standard definition of a sleep disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11301/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some occur during normal sleep. As an example, sleep starts (hypnic jerks) and sleep talking occur at some time in most normal sleepers.",
"     </li>",
"     <li>",
"      Some lie on the continuum between normal and abnormal. As an example, snoring without associated airway compromise, sleep disturbance, or other consequences is essentially normal, whereas heavy snoring is often part of obstructive sleep apnea.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     OTHER SLEEP DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep disorders that are due to environmental factors (eg, noise, temperature, restless bed partner) are classified here, along with sleep disorders that cannot be appropriately classified according to the 2nd edition of the International Classification of Sleep Disorders (ICSD-2) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11301/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     APPENDICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2nd edition of the International Classification of Sleep Disorders (ICSD-2) includes two appendices [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11301/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Appendix A includes diagnoses that can be classified as medical or neurologic disorders (eg, sleep related epilepsy or headaches, fibromyalgia, sleep related coronary ischemia)",
"     </li>",
"     <li>",
"      Appendix B is a guide to psychiatric disorders frequently encountered in sleep medicine and is intended for the non-psychiatric clinician",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/4/38978?source=see_link\">",
"       \"Patient information: Daytime sleepiness (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/16/2306?source=see_link\">",
"       \"Patient information: Insomnia (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 2nd edition of the International Classification of Sleep Disorders (ICSD-2) classifies sleep disorders into eight major categories. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'ICSD-2 system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The eight major categories of sleep disorders include insomnia, sleep related breathing disorders, hypersomnias of central origin, circadian rhythm disorders, parasomnias, sleep related movement disorders, isolated symptoms and normal variants, and other sleep disorders. (See related sections above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Academy of Sleep Medicine. International classification of sleep disorders, 2nd ed: Diagnostic and coding manual, American Academy of Sleep Medicine, Westchester, IL 2005.",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7700 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-F6FDDAB425-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_2_11301=[""].join("\n");
var outline_f11_2_11301=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ICSD-2 SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Impact on other classification systems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INSOMNIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SLEEP RELATED BREATHING DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HYPERSOMNIA OF CENTRAL ORIGIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CIRCADIAN RHYTHM SLEEP DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PARASOMNIAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SLEEP RELATED MOVEMENT DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ISOLATED SYMPTOMS AND NORMAL VARIANTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      OTHER SLEEP DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      APPENDICES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44502?source=related_link\">",
"      Central sleep apnea: Risk factors, clinical presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39239?source=related_link\">",
"      Central sleep apnea: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25913?source=related_link\">",
"      Clinical features and diagnosis of narcolepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4487?source=related_link\">",
"      Definition and consequences of sleep deprivation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35861?source=related_link\">",
"      Jet lag",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4758?source=related_link\">",
"      Overview of insomnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=related_link\">",
"      Overview of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/4/38978?source=related_link\">",
"      Patient information: Daytime sleepiness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/16/2306?source=related_link\">",
"      Patient information: Insomnia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/51/38710?source=related_link\">",
"      Performance and safety risks of sleep deprivation and sleep disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=related_link\">",
"      Restless legs syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/62/4071?source=related_link\">",
"      Treatment of narcolepsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_2_11302="Ethinyl estradiol and ethynodiol diacetate: Patient drug information";
var content_f11_2_11302=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ethinyl estradiol and ethynodiol diacetate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/22/12649?source=see_link\">",
"     see \"Ethinyl estradiol and ethynodiol diacetate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F168266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Kelnor&trade;;",
"     </li>",
"     <li>",
"      Zovia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F168267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Demulen&reg; 30",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700856",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not smoke while taking birth control pills. Cigarette smoking raises the chance of very bad heart and blood-related side effects. This chance is higher with age (older than 35 years of age) and with heavy smoking (15 or more cigarettes per day). Birth control pills do not stop the spread of diseases caused by having sex.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691546",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop pregnancy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease painful period (menstrual) cycles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691686",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat uterine bleeding due to hormonal imbalance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat pimples (acne).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691832",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat endometriosis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691841",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat women with hypogonadism.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702076",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ethinyl estradiol, ethynodiol diacetate, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Blood clots, breast cancer, diseased arteries in the brain, disease of a heart valve with problems, endometrial cancer, heart disease, high blood pressure, liver disease, liver tumor, very bad headache, tumor where estrogen makes it grow, or vaginal bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703789",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have surgery and need bed rest.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gallbladder disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698524",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), you will need to watch your blood sugar closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697308",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have migraine headaches, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698554",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do monthly breast self-exams and have a gynecologic exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort, dong quai, black cohosh, saw palmetto, red clover, or ginseng with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid cigarette smoking. People older than 35 years of age and/or smoking more than 15 cigarettes per day have more chance for heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698231",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Period (menstrual) changes. These include lots of bleeding, spotting, or bleeding between cycles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gallbladder disease, blood clots, heart attacks, and other blood vessel problems may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698598",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A lump in the breast or breast soreness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to use as you have been told by your doctor or read the package insert.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698535",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you miss 2 periods in a row, take a pregnancy test before starting a new dosing cycle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696559",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696550",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Missed dosing facts may be found in the package insert or call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12446 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-062E1C4994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_2_11302=[""].join("\n");
var outline_f11_2_11302=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168266\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168267\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027260\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027262\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027261\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027266\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027267\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027269\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027264\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027265\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027270\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027271\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/22/12649?source=related_link\">",
"      Ethinyl estradiol and ethynodiol diacetate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_2_11303="Chronic periodontitis";
var content_f11_2_11303=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62167&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62167&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 590px\">",
"   <div class=\"ttl\">",
"    Localized severe chronic periodontitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 570px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    69 year-old Caucasian female with generalized gingival recession and localized areas with deep probing depths and significant alveolar bone loss (ie, maxillary right posterior teeth).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_2_11303=[""].join("\n");
var outline_f11_2_11303=null;
var title_f11_2_11304="Bleeding after colonic polypectomy";
var content_f11_2_11304=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bleeding after colonic polypectomy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/2/11304/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/2/11304/contributors\">",
"     Jerome D Waye, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/2/11304/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/2/11304/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/2/11304/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/2/11304/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/2/11304/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postpolypectomy bleeding is the most common complication of colonic polypectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/1\">",
"     1",
"    </a>",
"    ], occurring in 0.3 to 6.1 percent of polypectomies in various reports [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/2-7\">",
"     2-7",
"    </a>",
"    ]. Bleeding can occur immediately following polypectomy or be delayed from hours to up to 29 days [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/2,5,6\">",
"     2,5,6",
"    </a>",
"    ]. The severity of bleeding ranges from arterial pumping to minor oozing. The risk is related to the type and size of the polyp, the technique of polypectomy, and the coagulation status of the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/3-5,8-11\">",
"     3-5,8-11",
"    </a>",
"    ]. Bleeding can be controlled endoscopically in the majority of patients. Thus, those who perform polypectomy should also have the ability to perform hemostasis and should have the necessary tools available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IMMEDIATE BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate bleeding has been observed in approximately 1.5 percent of polypectomies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/2,12\">",
"     2,12",
"    </a>",
"    ]. The risk is increased when blended current (rather than pure coagulation current) is used [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/13\">",
"     13",
"    </a>",
"    ], when the snare is pulled through the polyp without the use of cautery (\"cheese wiring\") in patients with coagulation disorders (although bleeding is not a problem with small polyps removed in this manner [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/14\">",
"     14",
"    </a>",
"    ]), and it is more likely with large polyps, those with a thick stalk, and polyps that are sessile [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a multicenter study, immediate bleeding was observed in 2.8 percent of 9336 polypectomies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/15\">",
"     15",
"    </a>",
"    ]. Independent risk factors for bleeding included age &ge;65 years, cardiovascular or chronic renal disease, use of anticoagulants, polyp size greater than 1 cm, polyp morphology, poor bowel preparation, cutting mode of electrosurgical current, and inadvertent cutting of a polyp before current application. They also found that pedunculated polyps and sessile polyps over 1 cm in diameter are more likely to bleed immediately after removal. This is similar to our experience, where the risk of significant bleeding is greatest with sessile polyps larger than 2.5 cm in diameter, followed by those with a thick stalk; significant bleeding is least likely to occur if a polyp is mistakenly pulled off with a snare, since this only happens with relatively small polyps.",
"   </p>",
"   <p>",
"    Polyps less than 1 cm in diameter have been safely removed in patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy who have discontinued warfarin for 36 hours (to avoid a supratherapeutic INR). In a report of 225 polypectomies in 123 anticoagulated patients, three patients bled (one requiring treatment) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/16\">",
"     16",
"    </a>",
"    ]. All patients in the study had prophylactic endoscopic clips applied to their polypectomy sites.",
"   </p>",
"   <p>",
"    Most bleeding that occurs immediately after resection can be controlled by the endoscopist [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/2\">",
"     2",
"    </a>",
"    ]. The technique for controlling bleeding depends upon the severity of bleeding, the type of polyp, and individual preference. A combination of techniques is frequently required (see below). Patients whose polypectomies were performed on an ambulatory basis may be sent home after hemostasis has been achieved, assuming that the bleeding was not torrential, and the patient was stable throughout the bleeding episode. We have not had any patient return with further bleeding within 24 hours following treatment of immediate postpolypectomy bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pedunculated polyps",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Application of pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate bleeding after resection of a pedunculated polyp can usually be stopped by regrasping the pedicle with a snare and holding pressure on the pedicle to stop blood flow, permitting the hemostatic cascade to occur. Retransection of the pedicle can be performed but is not the preferred approach since there may be too little of the pedicle remaining to regrasp if bleeding recommences. Holding a snare around a bleeding pedicle tightly for five minutes will usually result in hemostasis. Reapplication of pressure for an additional five minutes will almost always result in cessation of bleeding when bleeding recurs upon loosening the snare.",
"   </p>",
"   <p>",
"    Once active bleeding is controlled, there is usually no need for additional hemostatic measures, although application of bipolar cautery (BICAP) to the bleeding site or injection with epinephrine or application of endoclips is reasonable. Pretransection epinephrine injection has been suggested, but its efficacy has not been demonstrated. Because of the low risk of immediate bleeding, most endoscopists do not preinject the stalk of pedunculated polyps with epinephrine (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Epinephrine injection'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Epinephrine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several additional measures used alone or in combination can be effective in patients in whom bleeding cannot be controlled using the regrasping maneuver described above (such as those in whom the residual stalk cannot be ensnared). The bleeding site can be injected with epinephrine; a 1:10,000 dilution of epinephrine is commonly used, although some use a 1:20,000 dilution to reduce the risk of cardiovascular complications [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/17\">",
"     17",
"    </a>",
"    ]. While catecholamine levels rise following epinephrine injection for actively bleeding peptic ulcers in the upper GI tract, these levels have not been associated with any adverse cardiac events [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Cautery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another treatment option is to treat the bleeding site with cautery. This can be achieved with thermal probes, BICAP, or the tip of a polypectomy snare. When a thermal probe or BICAP is used, the current delivered should be decreased by approximately 50 percent relative to that used in the upper GI tract because the colon wall is very thin. The heater probe can be set at 15 J and the BICAP at 10 to 15W. Multiple applications at these power settings appear to be safe in the colon. In addition, it is not wise to apply a great deal of force, as is recommended in the upper intestinal tract, due to the increased risk of perforation. The water jet from thermal probes is extremely useful for precise localization of the bleeding site to permit accurate probe application. When the tip of the polypectomy snare is used as a cautery device, the setting does not need to be changed from that used during polypectomy; however, the snare-tip method is associated with an increased risk of a deep burn to the colon wall.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Hemoclips",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding can also be controlled by placement of hemoclips on the pedicle [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. The clips are especially useful for bleeding from flat polypectomy sites, but have also been used successfully to stop arterial pulsatile bleeding from the severed stalk of pedunculated polyps [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14712?source=see_link\">",
"     \"Endoclip therapy in the gastrointestinal tract: Bleeding lesions and beyond\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the clip application device is somewhat cumbersome, the applicator has been improved over the past few years. We use endoclips, like endoloops, to seal a postpolypectomy site in patients who have bleeding diatheses (see below). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14712?source=see_link\">",
"     \"Endoclip therapy in the gastrointestinal tract: Bleeding lesions and beyond\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Loops and band ligators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often, when pedunculated polyps are resected by snare polypectomy, even though a long pedicle may be transected in its mid portion, the residual stalk may contract immediately leaving a flat polypectomy site. The phenomenon of pedicle disappearance may result in a situation where there is no protuberant stalk remaining on the colon wall to regrasp with a snare. If a sufficient length of pedicle remains after resection, an endoloop can be applied to the bleeding stalk for hemostasis.",
"   </p>",
"   <p>",
"    Massive immediate and delayed postpolypectomy bleeding has also been managed by band ligation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Care must be taken to avoid high suction pressure since the thin muscularis propria and serosa could be entrapped within the band, leading to subsequent full thickness necrosis. Endoscopic ultrasound (EUS) has demonstrated that the colon wall varies in thickness from 1.06 to 1.83 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/25\">",
"     25",
"    </a>",
"    ]. Approximately one-third of the thickness of the colon wall consists of mucosa, one-third submucosa, and the rest muscularis propria. High suction can easily pull the thin muscle layer into the banding device, leading to full thickness strangulation and perforation when the tissue sloughs. Band ligation is probably unsafe in the right colon where other methods to achieve hemostasis are preferable [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Sessile polyps",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with pedunculated polyps, there are several options to control bleeding following excision of a sessile polyp.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The bleeding site can be injected with dilute epinephrine (1:10,000) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/27\">",
"       27",
"      </a>",
"      ]. Several mL may be required to stop the bleeding. The desired effect is a large bleb at the bleeding site with several injections made around the bleeding site.",
"     </li>",
"     <li>",
"      The hot biopsy forceps can be used as a cautery probe by direct application of monopolar current (",
"      <a class=\"graphic graphic_picture graphicRef82749 \" href=\"UTD.htm?0/36/578\">",
"       picture 1",
"      </a>",
"      ). Repeated light touching of the activated hot biopsy forceps to the tissue results in better fulguration than continuous pressure since the latter may cause heating of tissue without hemostasis, whereas creating a spark results in a better coagulum. A spark is formed by allowing the current to jump across an air-space by moving the activated tip close to, but not in direct contact with tissue. The tip of a snare can also be used as a coagulation probe, but as noted above there is a possibility of a deep burn of the colon wall. The setting of the electrosurgical unit for either the hot biopsy forceps or cautery with the snare tip is the same as for polypectomy.",
"     </li>",
"     <li>",
"      Hemoclips can be placed directly on the bleeding site in an attempt to occlude the bleeding vessel [",
"      <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/20\">",
"       20",
"      </a>",
"      ]. The average number of clips required to achieve hemostasis in one report was 2.9 &plusmn; 2 [",
"      <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14712?source=see_link\">",
"       \"Endoclip therapy in the gastrointestinal tract: Bleeding lesions and beyond\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Oozing can be controlled with the argon plasma coagulator (",
"      <a class=\"graphic graphic_picture graphicRef62421 \" href=\"UTD.htm?40/61/41937\">",
"       picture 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34695?source=see_link\">",
"       \"Argon plasma coagulation in the management of gastrointestinal hemorrhage\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Prevention of immediate bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coagulation status should be optimized in patients who are scheduled to undergo colonoscopy with possible polypectomy. Recommendations regarding anticoagulants and antiplatelet agents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link\">",
"     \"Endoscopic procedures in patients with disorders of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, there are several techniques that can be applied prior to transection for prevention of bleeding during polypectomy. However, there have been no well-designed controlled trials to guide the selection of technique. Thus, the decision to use a prophylactic measure depends upon experience, preference, and an appraisal of the risk of bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28968?source=see_link\">",
"     \"Endoscopic removal of large colonic polyps\"",
"    </a>",
"    .) The following discussion will summarize our experience and preferences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Epinephrine injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epinephrine can be injected into the stalk of a pedunculated polyp or into the base of a sessile polyp prior to transection. However, the low risk of immediate bleeding following resection of such polyps does not justify its routine use. One controlled trial that evaluated this issue included 120 patients with 151 sessile polyps who were randomly assigned to prophylactic epinephrine injection or standard polypectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/28\">",
"     28",
"    </a>",
"    ]. A total of nine episodes of postpolypectomy bleeding were observed, two in the epinephrine group and seven in the control group. There was one case of perforation in each group. Although the differences in immediate bleeding reached statistical significance, the rate of bleeding observed in the control group was much higher than has been described in other reports, raising uncertainty regarding the generalizability of the findings. Similar considerations apply in interpreting another report that reached the same conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/29\">",
"     29",
"    </a>",
"    ]. A later study reported that there was no difference in the rates of overall, early, or late bleeding regardless of whether epinephrine was added to the saline solution for submucosal injections during endoscopic mucosal resection (EMR) of polyps over 10 mm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Detachable loops",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detachable nylon loop has been developed that can be placed over the stalk like a wire snare and tightened with a one-way silicone-rubber stopper. The stopper prevents opening of the loop once it has been closed. The fully assembled endoloop, with an accompanying over-sheath (to permit the soft nylon loop to slide through the instrument channel), has the same diameter as a snare sheath. Once extruded from the end of the delivery system, the loop can be maneuvered around the head of a polyp or onto the bleeding base under direct vision (",
"    <a class=\"graphic graphic_picture graphicRef59681 \" href=\"UTD.htm?24/22/24929\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef68387 \" href=\"UTD.htm?24/35/25139\">",
"     picture 4",
"    </a>",
"    ). There are two sizes of loops, with the smaller (2.5 cm in diameter) being best suited for capture of the postpolypectomy base, and the larger (4 cm in diameter) used prepolypectomy for hemostasis. The loops spontaneously slough in four to seven days, leaving residual shallow ulcers.",
"   </p>",
"   <p>",
"    A randomized control study using detachable snares or epinephrine stalk injection showed that both of these had a lower incidence of early bleeding following snare polypectomy of pedunculated polyps (&lt;2 percent) compared to snare transection alone (6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/31\">",
"     31",
"    </a>",
"    ]. As expected, large pedunculated polyps had more bleeding than those in the 10 to 19 mm range. Treatment of patients who had bleeding consisted of epinephrine injection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clips. A separate controlled trial found a significantly lower rebleeding rate with combination therapy using detachable snare plus epinephrine injection compared with epinephrine injection alone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the loop can be used for added hemostasis during or after polypectomy, we believe its greatest utility is after polypectomy, when the endoscopist is concerned about the site, and some bleeding is seen. Placement of the loop after polypectomy is usually easier than placement prior to polypectomy. The loop is deployed onto the base of a severed pedunculated polyp and left there for hemostasis. However, sometimes the resected pedicle flattens, leaving no protuberant stalk on which to place the loop [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/21\">",
"     21",
"    </a>",
"    ]. In this event, a two-channel endoscope can be used to grasp the bleeding site with a forceps while placing a loop over the bleeding site to strangulate the blood supply [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/33\">",
"     33",
"    </a>",
"    ]. It may also be possible to place the flexible loop into a transparent mucosectomy cap and, after suctioning the base of the polypectomy site into the cap, successfully deploy the loop on the residual pedicle [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/34\">",
"     34",
"    </a>",
"    ]. Occasionally, hemoclips and loops are deployed sequentially to stop bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is our opinion that loops should not be routinely placed on polyp pedicles, even large pedicles, because of the low risk of bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/2\">",
"     2",
"    </a>",
"    ]. Because the loops are somewhat flexible, they can be quite difficult to pass over the head of a large polyp. Under the best of circumstances, the detachable loop can be placed over a polyp and maneuvered toward the colon wall. After securing the loop, a snare must be placed over the top of the polyp and positioned above the loop ligature trying to avoid partial ensnaring of the loop (which would make transection impossible). Our experience is that the floppy loop can become entrapped within the interstices of a large polyp and, when tightened, actually constrict the polyp head rather than the pedicle, making subsequent transection of the stalk difficult or even impossible. Other problems with the loop include severing of the pedicle by over tightening, slipping of the loop, and insufficient tightening [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/21\">",
"     21",
"    </a>",
"    ]. We typically only use loops prior to polypectomy when removing pedunculated polyps from patients with known bleeding diatheses, such a clotting factor deficiencies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Hemoclips",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is possible to apply a hemoclip onto the base of a pedunculated polyp close to the bowel wall (",
"    <a class=\"graphic graphic_picture graphicRef56809 \" href=\"UTD.htm?9/52/10051\">",
"     picture 5",
"    </a>",
"    ) and snare the polyp above the clip using standard snare techniques. It is important that the wire snare does not touch the metal clip, lest an aberrant current pathway be activated, with a potential burn of the colon wall [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Our personal preference is to use the clips in case of bleeding and not to apply them prophylactically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14712?source=see_link\">",
"     \"Endoclip therapy in the gastrointestinal tract: Bleeding lesions and beyond\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DELAYED BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;There appear to be two general causes for postpolypectomy hemorrhage. One is sloughing of the eschar that covered a blood vessel. Dislodgement may be spontaneous or related to the passage of the fecal effluent across the eschar. Another cause is related to excavation of a zone of thermal necrosis induced by the electrothermal energy used to sever and cauterize the polypectomy site. Over several days, the zone of thermal necrosis excavates to the level of non-injured tissue. The actual zone of thermal necrosis is usually considerably deeper than is visualized at the time of polypectomy. The necrosis invariably involves some degree of the submucosa, which may lead to hemorrhage should it extend into a blood vessel.",
"   </p>",
"   <p>",
"    Delayed bleeding occurs in up to 2 percent of patients who have polyps removed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. It develops on average five to seven days after the procedure, but it can be seen from a few hours to 29 days later [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/2,5,6,38\">",
"     2,5,6,38",
"    </a>",
"    ]. The risk is increased in the elderly, in patients with hypertension, when large sessile polyps are removed, when polyps are removed from the right colon, and when pure coagulation current was used for polypectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/6,39\">",
"     6,39",
"    </a>",
"    ]. The risk also increases with increasing polyp size [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/30,39\">",
"     30,39",
"    </a>",
"    ]. The incidence is approximately 1 percent for polyps less than 10 mm and 6.5 percent for those over 20 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Studies found that the risk of delayed bleeding increased by 9 to 13 percent for every 1 mm in polyp diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/39,42\">",
"     39,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A Canadian study of &gt;97,000 patients undergoing colonoscopy reported a rate of colonoscopy-related bleeding that resulted in a hospital admission within 30 days of colonoscopy of 1.64 per 1000 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/43\">",
"     43",
"    </a>",
"    ]. Having a polypectomy was one of the associated risk factors for delayed bleeding.",
"   </p>",
"   <p>",
"    Although use of NSAIDs and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    are commonly believed to increase the risk of delayed bleeding, there are no studies that corroborate this impression [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/10\">",
"     10",
"    </a>",
"    ]. In contrast, patients receiving anticoagulant therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ) do have an increased risk for delayed postpolypectomy bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/42,44,45\">",
"     42,44,45",
"    </a>",
"    ]. There usually is some slight bleeding that occurs when the coagulation eschar sloughs, which can occur several days to several weeks after polypectomy, when the patient's INR is at a therapeutic level. Bleeding from the sloughed eschar in an anticoagulated patient can become a potentially serious matter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link\">",
"     \"Endoscopic procedures in patients with disorders of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A retrospective study looked at 425 patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy and 800 matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/45\">",
"     45",
"    </a>",
"    ]. Most of the patients had their warfarin stopped four days prior to the colonoscopy and the mean INR for patients taking warfarin was 1.3 the day prior to the colonoscopy. Most patients resumed their warfarin the evening of the colonoscopy. The overall rate of postpolypectomy bleeding was 1 percent. Bleeding was more common in patients receiving warfarin compared to those not on warfarin (2.6 percent versus 0.2 percent). On predictive modeling, warfarin therapy was an independent predictor of postpolypectomy bleeding (adjusted odds ratio 11.6).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Management of delayed bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most polypectomy bleeding can be managed endoscopically, with only the unusual case requiring surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/6,46\">",
"     6,46",
"    </a>",
"    ]. About half of patients who present to the hospital with hematochezia within six hours to 14 days after polypectomy require blood transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/42\">",
"     42",
"    </a>",
"    ]. Colonoscopy should be performed urgently",
"    <strong>",
"     i",
"    </strong>",
"    n patients who appear to be actively bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/41\">",
"     41",
"    </a>",
"    ]. Blood is a cathartic and usually cleans residual stool out of the colon. In our experience, the bleeding site can be visualized adequately without other preparation even in patients where the polypectomy was on the right side of the colon.",
"   </p>",
"   <p>",
"    The frequency with which patients pass bloody bowel movements is a good indicator of whether bleeding is ongoing. Bowel movements are frequent and bloody in those with active bleeding, while the cessation of bleeding is almost always heralded by the absence of stooling. In patients who present with ongoing bloody bowel movements, an urgent unprepped colonoscopy should be performed as soon as the endoscopy unit can be made available. On the other hand, it is generally safe to wait and observe while applying conservative therapy if bowel movements have stopped. However, urgent endoscopic examination should be performed if bleeding resumes during observation. If the bleeding has stopped spontaneously, it is unusual for it to resume. As a result, there is generally no need to repeat the colonoscopic examination to evaluate or treat the presumed site of bleeding in a patient whose bleeding has stopped.",
"   </p>",
"   <p>",
"    The timing of intervention also depends upon the estimated rate of bleeding. If there are frequent bloody bowel movements, and the patient becomes hemodynamically unstable, urgent colonoscopy should be performed. On the other hand, if small amounts of blood are being passed per rectum, conservative treatment may be considered. The best time to perform an urgent colonoscopic examination is when the full endoscopy staff is present, and that is usually during the hours of operation of the endoscopy unit. If patients come to the emergency department late after hours, or in the early hours of the morning, it may be prudent to give the patient an oral electrolyte lavage and perform the colonoscopic examination within the next five to six hours when the endoscopy unit is open and the colon is cleaner and easier to visualize.",
"   </p>",
"   <p>",
"    Therapy is usually with epinephrine injection, often in combination with a thermal modality [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/6,46\">",
"     6,46",
"    </a>",
"    ]. It has been our experience that there is a considerable amount of swelling and firm induration at the polypectomy site within one to two days of polypectomy. This inflammatory response may cause obliteration of the separation of the layers of the colon wall, resulting in the inability for epinephrine injection to infiltrate into the tissue spaces, causing the injected fluid solution to run out of the needle hole at the injection site. However, the induration and resulting increased thickness of the wall makes the use of thermal modalities safer, so that repeated applications of a heater probe or BICAP can be used to achieve hemostasis.",
"   </p>",
"   <p>",
"    Hemoclips can also be effective; an average of 4.6 clips was required in one report of patients with severe bleeding that required hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/6\">",
"     6",
"    </a>",
"    ]. Angiography may be of benefit in the presence of severe bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24616?source=see_link\">",
"     \"Angiographic control of nonvariceal gastrointestinal bleeding in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whenever patients present with postpolypectomy hemorrhage, the surgical team should be notified, since it is impossible to know whether or not that patient will require emergency surgery. Surgery may be necessary when there is torrential hemorrhage. If only one polyp was removed, the endoscopist should be able to inform the surgeon as to which side of the colon needs to be resected. A subtotal colectomy may be required if several polyps were removed in various areas of the colon, and a colonoscopic examination cannot identify or exclude some of the distal-most sites. Angiographic therapy should be considered in cases of severe hemorrhage before proceeding to surgery. Super selective transcatheter arterial embolization with microcoils has been effective in controlling bleeding refractory to endoscopic therapy in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24616?source=see_link\">",
"     \"Angiographic control of nonvariceal gastrointestinal bleeding in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Prevention of delayed bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate measures should be taken in patients with hereditary or acquired hemostatic disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link\">",
"     \"Endoscopic procedures in patients with disorders of hemostasis\"",
"    </a>",
"    .) We request that the patient refrain from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for a week (based upon personal experience), despite the recommendation from the ASGE literature suggesting that polypectomy in the setting of aspirin is not contraindicated [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/49\">",
"     49",
"    </a>",
"    ]. Two studies have confirmed the lack of association between postpolypectomy bleeding and aspirin [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/44,50\">",
"     44,50",
"    </a>",
"    ] or antiplatelet agents [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/44\">",
"     44",
"    </a>",
"    ]. When patients have a coagulopathy or must return to an anticoagulation regimen, the risk of delayed bleeding may be reduced by the use of mechanical hemostatic tools such as clips (",
"    <a class=\"graphic graphic_picture graphicRef60247 \" href=\"UTD.htm?33/27/34224\">",
"     picture 6",
"    </a>",
"    ) or endoloops (see above). On the other hand, the routine use of hemoclips to close postpolypectomy ulcers did not reduce bleeding rates in a randomized controlled trial involving 413 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/40\">",
"     40",
"    </a>",
"    ]. Similarly, prophylactic use of argon plasma coagulation did not reduce delayed bleeding in a randomized controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11304/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Postpolypectomy diet does not appear to be a factor in delayed bleeding except (in our experience) in patients in whom the polypectomy leaves a large mucosal defect. We often suggest a liquid diet for 24 hours in such patients followed by a day of soft food. For all other polypectomy patients, a regular diet is permitted, with a suggestion that the first meal be \"light.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postpolypectomy hemorrhage is the most common postpolypectomy complication.",
"     </li>",
"     <li>",
"      Immediate bleeding has been observed in approximately 1.5 percent of polypectomies. The technique for controlling bleeding depends upon the severity of bleeding, the type of polyp, and individual preference. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Immediate bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Delayed bleeding occurs in up to 2 percent of patients who have polyps removed. Most delayed polypectomy bleeding can be managed endoscopically, with only the unusual case requiring surgery. However, the surgical team should be notified. The timing and type of intervention depends upon whether bleeding is believed to be ongoing, and the estimated rate of bleeding. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Delayed bleeding'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Most patients with significant active bleeding require stabilization and urgent colonoscopy.",
"     </li>",
"     <li>",
"      Patients with delayed bleeding who appear to have stopped bleeding or those with only minor bleeding may be managed by observation with elective colonoscopy performed if bleeding continues or resumes.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/1\">",
"      Rex DK, Lewis BS, Waye JD. Colonoscopy and endoscopic therapy for delayed post-polypectomy hemorrhage. Gastrointest Endosc 1992; 38:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/2\">",
"      Waye JD, Lewis BS, Yessayan S. Colonoscopy: a prospective report of complications. J Clin Gastroenterol 1992; 15:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/3\">",
"      Gibbs DH, Opelka FG, Beck DE, et al. Postpolypectomy colonic hemorrhage. Dis Colon Rectum 1996; 39:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/4\">",
"      Waye JD, Kahn O, Auerbach ME. Complications of colonoscopy and flexible sigmoidoscopy. Gastrointest Endosc Clin N Am 1996; 6:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/5\">",
"      Rosen L, Bub DS, Reed JF 3rd, Nastasee SA. Hemorrhage following colonoscopic polypectomy. Dis Colon Rectum 1993; 36:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/6\">",
"      Sorbi D, Norton I, Conio M, et al. Postpolypectomy lower GI bleeding: descriptive analysis. Gastrointest Endosc 2000; 51:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/7\">",
"      Levin TR, Zhao W, Conell C, et al. Complications of colonoscopy in an integrated health care delivery system. Ann Intern Med 2006; 145:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/8\">",
"      Singaram C, Torbey CF, Jacoby RF. Delayed postpolypectomy bleeding. Am J Gastroenterol 1995; 90:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/9\">",
"      Nakajima H, Takami H, Yamagata K, et al. Aspirin effects on colonic mucosal bleeding: implications for colonic biopsy and polypectomy. Dis Colon Rectum 1997; 40:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/10\">",
"      Shiffman ML, Farrel MT, Yee YS. Risk of bleeding after endoscopic biopsy or polypectomy in patients taking aspirin or other NSAIDS. Gastrointest Endosc 1994; 40:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/11\">",
"      Dyer WS, Quigley EM, Noel SM, et al. Major colonic hemorrhage following electrocoagulating (hot) biopsy of diminutive colonic polyps: relationship to colonic location and low-dose aspirin therapy. Gastrointest Endosc 1991; 37:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/12\">",
"      Consolo P, Luigiano C, Strangio G, et al. Efficacy, risk factors and complications of endoscopic polypectomy: ten year experience at a single center. World J Gastroenterol 2008; 14:2364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/13\">",
"      Van Gossum A, Cozzoli A, Adler M, et al. Colonoscopic snare polypectomy: analysis of 1485 resections comparing two types of current. Gastrointest Endosc 1992; 38:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/14\">",
"      Tappero G, Gaia E, De Giuli P, et al. Cold snare excision of small colorectal polyps. Gastrointest Endosc 1992; 38:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/15\">",
"      Kim HS, Kim TI, Kim WH, et al. Risk factors for immediate postpolypectomy bleeding of the colon: a multicenter study. Am J Gastroenterol 2006; 101:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/16\">",
"      Friedland S, Sedehi D, Soetikno R. Colonoscopic polypectomy in anticoagulated patients. World J Gastroenterol 2009; 15:1973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/17\">",
"      Jensen DM, Machicado GA, Jutabha R, Kovacs TO. Urgent colonoscopy for the diagnosis and treatment of severe diverticular hemorrhage. N Engl J Med 2000; 342:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/18\">",
"      Sung JY, Chung SC, Low JM, et al. Systemic absorption of epinephrine after endoscopic submucosal injection in patients with bleeding peptic ulcers. Gastrointest Endosc 1993; 39:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/19\">",
"      Binmoeller KF, Thonke F, Soehendra N. Endoscopic hemoclip treatment for gastrointestinal bleeding. Endoscopy 1993; 25:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/20\">",
"      Parra-Blanco A, Kaminaga N, Kojima T, et al. Hemoclipping for postpolypectomy and postbiopsy colonic bleeding. Gastrointest Endosc 2000; 51:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/21\">",
"      Matsushita M, Hajiro K, Takakuwa H, et al. Ineffective use of a detachable snare for colonoscopic polypectomy of large polyps. Gastrointest Endosc 1998; 47:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/22\">",
"      Pfaffenbach B, Adamek RJ, Wegener M. Endoscopic band ligation for treatment of post-polypectomy bleeding. Z Gastroenterol 1996; 34:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/23\">",
"      Slivka A, Parsons WG, Carr-Locke DL. Endoscopic band ligation for treatment of post-polypectomy hemorrhage. Gastrointest Endosc 1994; 40:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/24\">",
"      Witte JT. Band ligation for colonic bleeding: modification of multiband ligating devices for use with a colonoscope. Gastrointest Endosc 2000; 52:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/25\">",
"      Tsuga K, Haruma K, Fujimura J, et al. Evaluation of the colorectal wall in normal subjects and patients with ulcerative colitis using an ultrasonic catheter probe. Gastrointest Endosc 1998; 48:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/26\">",
"      Barker KB, Arnold HL, Fillman EP, et al. Safety of band ligator use in the small bowel and the colon. Gastrointest Endosc 2005; 62:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/27\">",
"      Conio M, Repici A, Demarquay JF, et al. EMR of large sessile colorectal polyps. Gastrointest Endosc 2004; 60:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/28\">",
"      Hsieh YH, Lin HJ, Tseng GY, et al. Is submucosal epinephrine injection necessary before polypectomy? A prospective, comparative study. Hepatogastroenterology 2001; 48:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/29\">",
"      Dobrowolski S, Dobosz M, Babicki A, et al. Prophylactic submucosal saline-adrenaline injection in colonoscopic polypectomy: prospective randomized study. Surg Endosc 2004; 18:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/30\">",
"      Lee SH, Chung IK, Kim SJ, et al. Comparison of postpolypectomy bleeding between epinephrine and saline submucosal injection for large colon polyps by conventional polypectomy: a prospective randomized, multicenter study. World J Gastroenterol 2007; 13:2973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/31\">",
"      Di Giorgio P, De Luca L, Calcagno G, et al. Detachable snare versus epinephrine injection in the prevention of postpolypectomy bleeding: a randomized and controlled study. Endoscopy 2004; 36:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/32\">",
"      Paspatis GA, Paraskeva K, Theodoropoulou A, et al. A prospective, randomized comparison of adrenaline injection in combination with detachable snare versus adrenaline injection alone in the prevention of postpolypectomy bleeding in large colonic polyps. Am J Gastroenterol 2006; 101:2805; quiz 2913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/33\">",
"      Soetikno RM, Friedland S, Lewit V, Woodford S. Lift and ligate: a new technique to treat a bleeding polypectomy stump. Gastrointest Endosc 2000; 52:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/34\">",
"      Zach&auml;us M, K&uuml;nzel U, Halm U. Bleeding prophylaxis after polypectomy by colonoscopic application of a detachable snare with a mucosectomy cap. Endoscopy 2008; 40 Suppl 2:E159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/35\">",
"      Uno Y, Satoh K, Tuji K, et al. Endoscopic ligation by means of clip and detachable snare for management of colonic postpolypectomy hemorrhage. Gastrointest Endosc 1999; 49:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/36\">",
"      Iida Y, Miura S, Munemoto Y, et al. Endoscopic resection of large colorectal polyps using a clipping method. Dis Colon Rectum 1994; 37:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/37\">",
"      Katsinelos P, Chatzimavroudis G, Papaziogas B, et al. Endoclipping-assisted resection of large colorectal polyps. Surg Laparosc Endosc Percutan Tech 2008; 18:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/38\">",
"      Watabe H, Yamaji Y, Okamoto M, et al. Risk assessment for delayed hemorrhagic complication of colonic polypectomy: polyp-related factors and patient-related factors. Gastrointest Endosc 2006; 64:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/39\">",
"      Buddingh KT, Herngreen T, Haringsma J, et al. Location in the right hemi-colon is an independent risk factor for delayed post-polypectomy hemorrhage: a multi-center case-control study. Am J Gastroenterol 2011; 106:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/40\">",
"      Shioji K, Suzuki Y, Kobayashi M, et al. Prophylactic clip application does not decrease delayed bleeding after colonoscopic polypectomy. Gastrointest Endosc 2003; 57:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/41\">",
"      Church JM. Experience in the endoscopic management of large colonic polyps. ANZ J Surg 2003; 73:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/42\">",
"      Sawhney MS, Salfiti N, Nelson DB, et al. Risk factors for severe delayed postpolypectomy bleeding. Endoscopy 2008; 40:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/43\">",
"      Rabeneck L, Paszat LF, Hilsden RJ, et al. Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice. Gastroenterology 2008; 135:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/44\">",
"      Hui AJ, Wong RM, Ching JY, et al. Risk of colonoscopic polypectomy bleeding with anticoagulants and antiplatelet agents: analysis of 1657 cases. Gastrointest Endosc 2004; 59:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/45\">",
"      Witt DM, Delate T, McCool KH, et al. Incidence and predictors of bleeding or thrombosis after polypectomy in patients receiving and not receiving anticoagulation therapy. J Thromb Haemost 2009; 7:1982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/46\">",
"      Ker TS, Wasserberg N, Beart RW Jr. Colonoscopic perforation and bleeding of the colon can be treated safely without surgery. Am Surg 2004; 70:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/47\">",
"      Carlyle DR, Goldstein HM. Angiographic management of bleeding following transcolonoscopic polypectomy. Am J Dig Dis 1975; 20:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/48\">",
"      Mezawa S, Homma H, Murase K, et al. Superselective transcatheter embolization for acute lower gastrointestinal hemorrhage after endoscopic mucosal resection: a report of 3 cases. Hepatogastroenterology 2003; 50:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/49\">",
"      Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures. American Society for Gastrointestinal Endoscopy. Gastrointest Endosc 1998; 48:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/50\">",
"      Yousfi M, Gostout CJ, Baron TH, et al. Postpolypectomy lower gastrointestinal bleeding: potential role of aspirin. Am J Gastroenterol 2004; 99:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11304/abstract/51\">",
"      Lee CK, Lee SH, Park JY, et al. Prophylactic argon plasma coagulation ablation does not decrease delayed postpolypectomy bleeding. Gastrointest Endosc 2009; 70:353.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2671 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-AC55A795B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_2_11304=[""].join("\n");
var outline_f11_2_11304=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IMMEDIATE BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pedunculated polyps",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Application of pressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Epinephrine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Cautery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Hemoclips",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Loops and band ligators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Sessile polyps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Prevention of immediate bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Epinephrine injection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Detachable loops",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Hemoclips",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DELAYED BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Management of delayed bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Prevention of delayed bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2671\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2671|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/36/578\" title=\"picture 1\">",
"      Postpolypectomy bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/61/41937\" title=\"picture 2\">",
"      Bleeding sessile polyp APC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/22/24929\" title=\"picture 3\">",
"      Pedunculated polyp endloop",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/35/25139\" title=\"picture 4\">",
"      Pedunculated polyp endoloop II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/52/10051\" title=\"picture 5\">",
"      Prophylactic hemoclip Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/27/34224\" title=\"picture 6\">",
"      Hemoclips after polypectomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24616?source=related_link\">",
"      Angiographic control of nonvariceal gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34695?source=related_link\">",
"      Argon plasma coagulation in the management of gastrointestinal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14712?source=related_link\">",
"      Endoclip therapy in the gastrointestinal tract: Bleeding lesions and beyond",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=related_link\">",
"      Endoscopic procedures in patients with disorders of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28968?source=related_link\">",
"      Endoscopic removal of large colonic polyps",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_2_11305="Managing an episode of severe or prolonged uterine bleeding";
var content_f11_2_11305=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Managing an episode of severe or prolonged uterine bleeding",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/2/11305/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/2/11305/contributors\">",
"     Howard A Zacur, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/2/11305/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/2/11305/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/2/11305/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/2/11305/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/2/11305/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An episode of heavy or prolonged uterine bleeding may occur either in women with normal menses or those with chronic abnormal uterine bleeding. These women present to a clinician's office or emergency room complaining of vaginal bleeding that is severe or has lasted for many days or weeks. Consequences of such episodes depend upon the volume of bleeding, and range from patient anxiety and interference with daily activities to severe anemia and hypovolemia. Evaluation and management of women experiencing such episodes must be expedited to establish the source of bleeding and prevent or treat excessive blood loss.",
"   </p>",
"   <p>",
"    Evaluation and management of an episode of heavy or prolonged uterine bleeding will be reviewed here. The general evaluation and treatment of abnormal uterine bleeding, uterine bleeding in pregnancy, and approach to a woman with vaginal bleeding in the emergency department are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23944?source=see_link\">",
"     \"Terminology and evaluation of abnormal uterine bleeding in premenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=see_link\">",
"     \"Chronic menorrhagia or anovulatory uterine bleeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15465?source=see_link\">",
"     \"Overview of the etiology and evaluation of vaginal bleeding in pregnant women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20920?source=see_link\">",
"     \"Approach to vaginal bleeding in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no standard definition of acute uterine bleeding. Acute uterine bleeding has been described as excessively heavy or prolonged bleeding of uterine origin sufficient in volume as to require urgent or emergent intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11305/abstract/1\">",
"     1",
"    </a>",
"    ]. This may occur with ovulatory or anovulatory bleeding. In this review, we will use the term acute to refer to bleeding that is profuse, and not only of sudden onset.",
"   </p>",
"   <p>",
"    Prolonged menses are defined as longer than seven days; in this review, we will apply this definition to either ovulatory or anovulatory bleeding and address women with an isolated episode of prolonged bleeding. Management of chronic prolonged uterine bleeding is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=see_link\">",
"     \"Chronic menorrhagia or anovulatory uterine bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with heavy or prolonged uterine bleeding generally complain of heavy vaginal bleeding that may soak through clothing or onto bedding. Women with this symptom also often report passing blood clots. The current episode may represent either a new onset of bleeding or an exacerbation of existing bleeding; it may be continuous or intermittent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of evaluation of a woman who complains of heavy or prolonged bleeding from the vagina are to establish hemodynamic instability, identify the source of bleeding, and evaluate the volume of blood loss.",
"   </p>",
"   <p>",
"    Upon initial presentation, the most important steps in evaluating a woman with heavy or prolonged vaginal bleeding are to assess hemodynamic stability and perform a pregnancy test. Vaginal bleeding in pregnant women is discussed in detail separately. Once these steps of the evaluation are complete, the approach to further evaluation can be determined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15465?source=see_link\">",
"     \"Overview of the etiology and evaluation of vaginal bleeding in pregnant women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Assess hemodynamic stability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vital signs are the first step in the evaluation of women who present with heavy or prolonged vaginal bleeding. In women who are not stable, immediate supportive measures (eg, fluid resuscitation, blood transfusion) should be initiated and testing for anemia and an expedited assessment for the source of bleeding are performed. In women who are stable, a more detailed evaluation may proceed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Evaluate for anemia and coagulopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A hematocrit is sent to assess for anemia; clotting studies are sent in women with suspected coagulopathy. A bleeding diathesis may be either the etiology of the bleeding or may be secondary to other factors associated with the bleeding. Laboratory testing may be deferred until after the history and physical examination are performed in hemodynamically stable patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8073?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathogenesis and etiology of disseminated intravascular coagulation\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Confirm uterine source and assess volume of bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confirmation of the uterus as the source of bleeding can be made through both history and physical examination. This section describes a focused initial evaluation of women with profuse or prolonged bleeding. Once the bleeding has been controlled, a comprehensive evaluation can be performed to identify its etiology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23944?source=see_link&amp;anchor=H13#H13\">",
"     \"Terminology and evaluation of abnormal uterine bleeding in premenopausal women\", section on 'Evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2711?source=see_link&amp;anchor=H15#H15\">",
"     \"Postmenopausal uterine bleeding\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of precipitating events (eg, trauma, surgery, recent pregnancy) and previous episodes of heavy, prolonged, or spontaneous bleeding from the genital tract or other sites is elicited. Women are also asked about uterine pathology (eg, fibroids) and medications or family history that suggest a bleeding diathesis. Bleeding that is associated with urination or defecation suggests, but does not confirm, bleeding from the urethra or anus.",
"   </p>",
"   <p>",
"    A patient should be asked about the duration, pattern, and volume of bleeding. Prolonged bleeding is defined as longer than seven days, as noted above (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Terminology'",
"    </a>",
"    above). Heavy and prolonged bleeding may both occur within a single episode, since the rate of bleeding may suddenly increase after days or weeks of moderate flow.",
"   </p>",
"   <p>",
"    Profuse or prolonged bleeding may be continuous or intermittent. A hiatus of bleeding of several hours may represent blood that has accumulated in the upper vagina and is released when a woman changes position from supine or seated to standing.",
"   </p>",
"   <p>",
"    The volume of bleeding can be estimated from the number of sanitary pads or tampons that have been soaked (",
"    <a class=\"graphic graphic_table graphicRef69390 \" href=\"UTD.htm?14/2/14379\">",
"     table 1",
"    </a>",
"    ). A typical definition of profuse bleeding is that it soaks a large sanitary pad or tampon at every hour or two and continues for two or more hours [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11305/abstract/2\">",
"     2",
"    </a>",
"    ]. United States regulations specify that each regular to super plus tampon absorbs 6 to 15 g of fluid, which equals approximately 6 to 15 mL of whole blood [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11305/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. However, assessing the volume of blood loss by counting tampons or pads appears to be inaccurate. Clinical studies have reported that the mean absorption ranges from 1 to 994 ml for different types of sanitary products and that absorbency varied greatly for products in a single package [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11305/abstract/5\">",
"     5",
"    </a>",
"    ]. The alkaline hematin method is the standard for determining menstrual blood loss from a tampon or sanitary pad and is used in research settings. As a comparison, the average amount of fluid loss during menstruation is 35 to 40 mL per five to seven day cycle, of which approximately one-third is whole blood and the rest is endometrial tissue fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11305/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]; excessive menstrual bleeding is defined as greater than 80 mL [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11305/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many of these episodes are self-limited. In such cases, immediate treatment is not necessary and the patient should be evaluated as appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23944?source=see_link\">",
"     \"Terminology and evaluation of abnormal uterine bleeding in premenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination of the external and internal anatomy of the female genital tract is crucial in confirming that source of bleeding is uterine rather than from another genital tract site (",
"    <a class=\"graphic graphic_table graphicRef74527 \" href=\"UTD.htm?25/45/26334\">",
"     table 2",
"    </a>",
"    ). The differential diagnosis of genital tract bleeding in women is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/18/35113?source=see_link\">",
"     \"Overview of causes of genital tract bleeding in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A complete pelvic examination is performed with the following focus:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assess the presence of active bleeding and its volume.",
"     </li>",
"     <li>",
"      Determine if the bleeding is originating from the vulva, vagina, cervical surface or os, urethra, or anus.",
"     </li>",
"     <li>",
"      Note any suspicious findings (eg, mass, laceration, ulceration, foreign body).",
"     </li>",
"     <li>",
"      Assess the size, contour, and tenderness of the uterus, which may suggest the presence of fibroids, adenomyosis, or infection.",
"     </li>",
"     <li>",
"      Examine the adnexa for a mass or tenderness, suggesting a tumor or infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, a general physical examination should be performed to look for signs of systemic illness, such as fever, ecchymoses, an enlarged thyroid gland, or evidence of hyperandrogenism (hirsutism, acne, clitoromegaly, or male pattern balding).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Identify structural abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine structural abnormalities can be identified with pelvic examination",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    imaging. Such information may help to guide management, but imaging should be deferred until the patient is hemodynamically stable. Pelvic ultrasound is the imaging study of choice since it can be performed quickly and yields useful images of the uterus and ovaries. Brisk uterine bleeding may make it difficult to perform or interpret sonographic imaging. Computed tomography and magnetic resonance imaging are more expensive, take longer to perform, and are unlikely to provide more information than ultrasound in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Sample the endometrium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial sampling should be performed in all patients who have an episode of profuse uterine bleeding, to exclude endometrial neoplasia or endometritis. Whether sampling is performed before, during, or after therapy depends upon the choice of initial therapy (ie, uterine curettage is both diagnostic and therapeutic) and whether the patient's hemodynamic status allows therapy to be deferred while sampling is performed. It is preferable to collect an endometrial specimen prior to hormonal therapy whenever possible, since hormonal alterations may interfere with interpretation of the sample.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of acute or prolonged uterine bleeding in nonpregnant women include anatomic uterine abnormalities (eg, fibroids, arteriovenous malformation), endocrinologic issues, or a bleeding diathesis. The differential diagnosis is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=see_link&amp;anchor=H4#H4\">",
"     \"Chronic menorrhagia or anovulatory uterine bleeding\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     APPROACH TO MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women should be triaged according to hemodynamic stability and rate of ongoing blood loss. The goal of therapy in all women is cessation of bleeding. Once this has been achieved, a treatment plan can be made for women who are likely to have recurrent bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     HEMODYNAMICALLY UNSTABLE WOMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodynamically unstable women with acute or prolonged uterine bleeding require immediate intervention. Woman who present to an ambulatory setting and are found to be hemodynamically unstable should be transferred immediately to an acute care setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Stabilizing the patient",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Fluid resuscitation and blood product replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodynamically unstable patients are prepared for resuscitation in the standard fashion: airway assessment, placement of two large bore (14 gauge or larger) peripheral intravenous lines, and type and cross-matching of blood in preparation for transfusion. Fluid resuscitation and replacement of red blood cell",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    plasma components are administered as appropriate (",
"    <a class=\"graphic graphic_table graphicRef78925 \" href=\"UTD.htm?19/52/20300\">",
"     table 3",
"    </a>",
"    )&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef69637 \" href=\"UTD.htm?13/38/13932\">",
"     table 4",
"    </a>",
"    ). Resuscitation of a woman with vaginal bleeding in an acute care setting is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20920?source=see_link&amp;anchor=H12#H12\">",
"     \"Approach to vaginal bleeding in the emergency department\", section on 'Determine hemodynamic status'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Intrauterine tamponade",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial step to decrease profuse uterine bleeding in a hemodynamically unstable woman is intrauterine tamponade. This approach will typically decrease bleeding and, in conjunction with appropriate administration of intravenous fluids and blood transfusion, stabilize the patient while more definitive therapy is implemented. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20920?source=see_link\">",
"     \"Approach to vaginal bleeding in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intrauterine tamponade can be achieved using either an intrauterine balloon or gauze packing. The steps for placing either of these are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Place a speculum in the vagina and visualize the cervical os.",
"     </li>",
"     <li>",
"      Sterilize the cervix by swabbing it three times with a large cotton swab or gauze soaked in iodine.",
"     </li>",
"     <li>",
"      Stabilize the cervix by placing a single tooth tenaculum or ring forceps on the anterior cervical lip.",
"     </li>",
"     <li>",
"      Grasp the balloon or gauze with a long Kelly or ring forceps and thread it in through the cervical os into the uterus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When a balloon is used, it is inflated after it is inserted into the uterus. Most commonly a 30 mL Foley catheter is used. With a 30 mL balloon in place, if brisk bleeding continues and the uterus is enlarged (the size of 12 or more weeks of gestation), a larger balloon may be required; the Bakri balloon used for postpartum hemorrhage has a 300 mL capacity (",
"    <a class=\"graphic graphic_figure graphicRef52635 \" href=\"UTD.htm?43/8/44164\">",
"     figure 1",
"    </a>",
"    )&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41929?source=see_link&amp;anchor=H13#H13\">",
"     \"Management of postpartum hemorrhage at vaginal delivery\", section on 'Uterine tamponade'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    When gauze is used, a continuous piece of gauze (eg, Kerlix&trade;) is preferred over smaller gauze pieces to avoid retained pieces of gauze upon removal. Gauze is placed until no further gauze can be admitted. Firm, but not excessive, pressure is used to avoid uterine perforation. The gauze can be impregnated with 5000 units thrombin in 5 mL sterile saline to enhance clotting. If packing does not control hemorrhage, in our clinical experience, repacking is unlikely to be effective.",
"   </p>",
"   <p>",
"    The distended tamponaded uterus causes discomfort, which can be treated with analgesics or a slight reduction in distending pressure, as long as tamponade is maintained. Devices used to tamponade the uterus should not be left in place for more than 24 hours. If the tamponade is not removed for the purpose of other treatment measures, then deflation is performed slowly, eg, 20",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    for a balloon or 5",
"    <span class=\"nowrap\">",
"     cm/hr",
"    </span>",
"    of gauze. We give broad spectrum antibiotics for infection prophylaxis to patients with an intrauterine balloon or packing in place.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Therapeutic measures",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Uterine curettage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine curettage is the treatment of choice for profuse uterine bleeding in women who are hemodynamically unstable. In most women and at most institutions, it can be performed rapidly, with cessation or significant decrease in bleeding in less than one hour. Other advantages of this treatment are that it is both diagnostic and therapeutic and it can be performed in women who wish to preserve fertility. A disadvantage of curettage is that it does not treat the underlying cause of uterine bleeding, so bleeding is likely to recur if no preventive therapy is initiated postoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11305/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no high quality data comparing uterine curettage with medical therapy in women with acute uterine bleeding. According to indirect data and clinical experience, medical therapy requires more time until bleeding subsides [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11305/abstract/11\">",
"     11",
"    </a>",
"    ]. An advantage of medical therapy is that its use avoids the risk of perioperative complications. Thus, we suggest medical therapy for women in whom a waiting period of three or more hours is not likely to result in the need for additional blood product transfusion or medical complications. Medical therapy is often beneficial in addition to curettage if bleeding persists after the procedure or to prevent recurrent bleeding.",
"   </p>",
"   <p>",
"    Curettage can be performed as a standard dilation and curettage (D&amp;C) or using a Karman cannula. Advantages of the Karman cannula over a D&amp;C are that it can be used in the office or emergency department and often does not require cervical dilation. On the other hand, the Karman procedure typically removes less tissue and, thus, it may be less effective at decreasing bleeding. The steps of each procedure are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/41/35480?source=see_link&amp;anchor=H8#H8\">",
"     \"Dilation and curettage\", section on 'Procedure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/8/131?source=see_link\">",
"     \"Endometrial sampling procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     High dose intravenous estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;High dose intravenous (IV) estrogen is beneficial in combination with other measures in hemodynamically unstable women with acute uterine bleeding; the use of IV estrogen alone is appropriate in some women (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Uterine curettage'",
"    </a>",
"    above). IV estrogen alone appears to result in cessation of bleeding in most women within five hours of the first dose [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11305/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of action of estrogen therapy is based on the denudation of the endometrium that results from profuse uterine bleeding. Estrogen promotes rapid regrowth of endometrium over the denuded epithelial surface, stabilizes lysosomal membranes, and stimulates proliferation of endometrial ground substance [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11305/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effectiveness of IV conjugated equine estrogen (CEE) therapy was illustrated in a randomized trial in which 34 women with excessive or prolonged uterine bleeding were assigned to IV CEE (Premarin 25 mg in 5 mL isotonic saline injected over two minutes with a dose repeated at three and five hours from the initial dose if bleeding continued) or placebo (lactose 200 mg) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11305/abstract/13\">",
"     13",
"    </a>",
"    ]. Within three hours of the first dose, there was no significant difference in the number of women in whom bleeding had stopped in the CEE versus placebo group (22 versus 36 percent). However, at five hours after the first dose, bleeding had stopped in significantly more women in the CEE versus placebo group (72 versus 38 percent); among the remaining five patients in the CEE group, bleeding persisted in two women at eight hours. Endometrial biopsy revealed no association between histology (benign, neoplasia, or endometritis) and success of therapy.",
"   </p>",
"   <p>",
"    An antiemetic is often required with this regimen. In the trial described above, intravenous CEE produced nausea and vomiting in 39 percent of treated patients compared with 13 percent in the placebo group [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11305/abstract/13\">",
"     13",
"    </a>",
"    ]. In women treated with IV estrogen, we give",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    IV 2.5 to 10 mg every three to four hours as needed.",
"   </p>",
"   <p>",
"    If bleeding does not subside after eight hours, IV estrogen should be stopped and other treatments employed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11305/abstract/13\">",
"     13",
"    </a>",
"    ]. If bleeding subsides, IV estrogen is discontinued and an oral maintenance regimen is prescribed; options include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral CEE &mdash; We use Premarin 2.5 mg four times per day until the bleeding subsides or is minimal. We do not continue this regimen for more than 21 to 25 days. The potency of the effect on liver proteins of 2.5 mg of premarin is approximately equivalent to 8 to 40 mcg of ethinyl estradiol [",
"      <a class=\"abstract\" href=\"UTD.htm?11/2/11305/abstract/14\">",
"       14",
"      </a>",
"      ]; it is, therefore, similar to or less than one dose of a 35 mcg oral contraceptive. After the estrogen is discontinued, a progestin should be given. We use oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      for 10 days.",
"     </li>",
"     <li>",
"      Oral contraceptive pill with 35 mcg estrogen &mdash; We use two pills per day for 5 days followed by once a day for 20 days. At the conclusion of oral therapy, women will have a withdrawal bleed that may be heavy, but is likely to last less than five to seven days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pulmonary embolism and thrombosis at other sites are potential complications of high dose estrogen therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11305/abstract/15\">",
"     15",
"    </a>",
"    ]. The minimum effective estrogen dose that controls bleeding should be administered to minimize the prevalence of side effects and the risk of complications. This therapy should be avoided in women with absolute contraindications to estrogen therapy (see",
"    <a class=\"local\" href=\"#H29\">",
"     'Women at risk of thrombosis'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Uterine artery embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine artery embolization as a first line therapy is reserved for women in whom the etiology of bleeding is a uterine arteriovenous malformation, since it is the most effective treatment for this condition. Use of embolization in unstable patients is limited because it usually cannot be performed as rapidly as other measures. In institutions in which embolization can be performed in a timely fashion, it can be an effective alternative to hysterectomy in women who wish to preserve their uterus.",
"   </p>",
"   <p>",
"    The safety of pregnancy after uterine artery embolization is uncertain; a systematic review and several case series of pregnancies following this procedure reported adverse outcomes in some pregnancies following uterine artery embolization, including miscarriage, preterm delivery, placental problems, and malpresentation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30408?source=see_link\">",
"     \"Interventional radiology in management of gynecological disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Hysterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the rare cases in which the above measures fail, hysterectomy is a last resort. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/46/32490?source=see_link&amp;anchor=H37#H37\">",
"     \"Abdominal hysterectomy\", section on 'Emergency or unplanned hysterectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     HEMODYNAMICALLY STABLE WOMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hormonal treatments are the mainstay of therapy for acute or prolonged uterine bleeding in hemodynamically stable women. For women with prolonged bleeding that is not profuse (soaking &lt;1 pad or tampon per hour), lower doses of oral contraceptives are the best option (see",
"    <a class=\"local\" href=\"#H25\">",
"     'High dose oral contraceptives'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     High dose oral estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;First line therapy for hemodynamically stable women is high dose oral estrogen. We give Premarin 2.5 mg four times per day until the bleeding subsides or is minimal. For women with moderate bleeding, we change the regimen to twice daily. We do not continue this regimen for more than 21 to 25 days. After the estrogen is discontinued, a progestin should be given; we use oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for 10 days. The potency of the effect on liver proteins of 2.5 mg of premarin is approximately equivalent to 8 to 40 mcg of ethinyl estradiol [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11305/abstract/14\">",
"     14",
"    </a>",
"    ]; it is, therefore, similar to or less than one dose of a 35 mcg oral contraceptive.",
"   </p>",
"   <p>",
"    Many women experience nausea and vomiting while taking high dose estrogen. An antiemetic (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"     promethazine",
"    </a>",
"    12.5 to 25 mg per rectum) should be prescribed, to be used as needed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11305/abstract/16\">",
"     16",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H20\">",
"     'High dose intravenous estrogen'",
"    </a>",
"    above). There are no data regarding the time course of therapeutic success with high dose oral estrogen. Based on the data for IV estrogen therapy and allowing for a delayed onset of action with oral administration, bleeding is likely to stop in most women within 10 hours after the first dose.",
"   </p>",
"   <p>",
"    Estrogen therapy alone is more effective than combined estrogen-progestin or progestin-alone therapy because progestins inhibit the synthesis of estrogen receptors and increase estradiol dehydrogenase, thereby impeding the rapid proliferation of endometrium induced by estrogen.",
"   </p>",
"   <p>",
"    This therapy should be avoided in women with absolute contraindications to estrogen therapy (see",
"    <a class=\"local\" href=\"#H29\">",
"     'Women at risk of thrombosis'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     High dose oral contraceptives",
"    </span>",
"    &nbsp;&mdash;&nbsp;High doses of oral contraceptives (OCs) (eg, an OC containing 35 mcg ethinyl estradiol taken two to four times daily) will cause bleeding to subside in most women within 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11305/abstract/1,16\">",
"     1,16",
"    </a>",
"    ]. We use a cascading regimen (ie, five pills on day 1, four pills on day 2, three pills on day 3, two pills on day 4, and one pill on day 5). For women with moderate bleeding, we start with three pills daily. An antiemetic medication should be prescribed (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"     promethazine",
"    </a>",
"    12.5 to 25 mg per rectum, as needed).",
"   </p>",
"   <p>",
"    Treatment with one pill daily of OCs should continue for at least one week after the bleeding subsides and then should be stopped for three to five days to allow for a withdrawal bleed. Standard dose OCs may then be restarted either to prevent recurrent menorrhagia or for contraception.",
"   </p>",
"   <p>",
"    Other combined estrogen-progestin contraceptives (vaginal ring, patch) are not used for treatment of an episode of profuse uterine bleeding, since it is not possible to vary the dose as precisely as with OCs.",
"   </p>",
"   <p>",
"    There are no data comparing treatment of estrogen alone versus estrogen-progestins in women with acute or prolonged uterine bleeding. As discussed above, physiologically it appears that treatment with estrogen alone is likely to be effective more rapidly than with a combined estrogen-progestin (see",
"    <a class=\"local\" href=\"#H24\">",
"     'High dose oral estrogen'",
"    </a>",
"    above). On the other hand, some women may prefer OCs due to familiarity or other reasons. We use OCs in women who can tolerate continued bleeding for 48 hours and prefer an OC to oral CEE.",
"   </p>",
"   <p>",
"    OC therapy should be avoided in women with absolute contraindications to estrogen or progestin therapy (see",
"    <a class=\"local\" href=\"#H29\">",
"     'Women at risk of thrombosis'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     High dose progestins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Profuse or prolonged uterine hemorrhage related to anovulation can also be treated with high dose progestins alone. In women with a thickened endometrium, progestins inhibit further endometrial growth and organize and support the estrogen-primed endometrium, allowing effective sloughing upon hormone withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11305/abstract/11\">",
"     11",
"    </a>",
"    ]. However, if profuse, prolonged bleeding has resulted in a denuded endometrium, progestins are unlikely to be effective. Diagnosis of anovulation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/25/20887?source=see_link&amp;anchor=H10#H10\">",
"     \"Initial approach to the premenopausal woman with abnormal uterine bleeding\", section on 'Anovulatory bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Options for progestin therapy include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      (10 to 20 mg two times per day)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"       megestrol acetate",
"      </a>",
"      (20 to 60 mg two times per day)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"       norethindrone",
"      </a>",
"      (5 mg once or twice per day)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Progestins are continued for at least 5 to 10 days [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11305/abstract/1,17,18\">",
"     1,17,18",
"    </a>",
"    ]. In anemic patients who can tolerate this regimen, a one- to two-month treatment period in conjunction with iron allows an increase in the hemoglobin concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of anemia due to iron deficiency\", section on 'Expected response'",
"    </a>",
"    .) Prolonged use of these drugs can cause acne, mood changes, weight gain, headache, and lipid abnormalities.",
"   </p>",
"   <p>",
"    A randomized trial of 40 women with acute uterine bleeding compared the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    (20 mg three times daily for seven days) to combined estrogen-progestin therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"     norethindrone",
"    </a>",
"    1",
"    <span class=\"nowrap\">",
"     mg/ethinyl",
"    </span>",
"    estradiol 35 mcg) three times daily for seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11305/abstract/1\">",
"     1",
"    </a>",
"    ]. Both regimens resulted in cessation of bleeding in approximately three days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Tranexamic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another medical therapy option is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    (1 to 1.5 g orally three to four times daily), which acts within two to three hours of administration [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11305/abstract/19\">",
"     19",
"    </a>",
"    ]. The drug exerts an antifibrinolytic effect by reversibly blocking lysine binding sites on plasminogen, thereby preventing fibrin degradation. Side effects from tranexamic acid include nausea, dizziness and diarrhea.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     Tranexamic acid",
"    </a>",
"    was approved by the United States Food and Drug Association in 2009 for treatment of menorrhagia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11305/abstract/20\">",
"     20",
"    </a>",
"    ]. The risk of thrombotic events with tranexamic acid is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11305/abstract/21-27\">",
"     21-27",
"    </a>",
"    ]. We use tranexamic acid only when other options have been unsuccessful and only in women who are not at a high risk of thrombosis. It therefore has limited use in women with contraindications to hormonal therapy, since these are mainly due to risk of thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Endometrial ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial ablation is an effective treatment for acute or prolonged uterine bleeding and is used in stable women in whom medical therapy is contraindicated or unsuccessful [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11305/abstract/28-32\">",
"     28-32",
"    </a>",
"    ]. This procedure precludes subsequent pregnancy. Either global or standard ablation may be performed. Hysteroscopy prior to ablation may be useful to identify and treat endometrial polyps or intracavitary leiomyomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=see_link\">",
"     \"An overview of endometrial ablation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential efficacy of endometrial ablation was illustrated in a report of 26 women with severe uterine bleeding who underwent ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11305/abstract/28\">",
"     28",
"    </a>",
"    ]. At one-year follow-up, 25 of the 26 women had decreased bleeding and had received no further medical or surgical therapy; one patient required a hysterectomy after 16 months in the setting of a leiomyoma and persistent uterine bleeding.",
"   </p>",
"   <p>",
"    For stable patients treated with surgical therapy, we suggest endometrial ablation over uterine curettage or uterine artery embolization. While all these procedures are minimally invasive, endometrial ablation is more likely to provide long-term improvement in uterine bleeding symptoms. On the other hand, curettage is preferred for women who desire to preserve fertility; the safety of pregnancy following embolization is uncertain (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Uterine curettage'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H21\">",
"     'Uterine artery embolization'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     WOMEN AT RISK OF THROMBOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen therapy is a standard treatment for uterine bleeding. Potential complications of estrogen therapy include venous thromboembolism (VTE) and coronary or cerebral thrombosis. Therefore, estrogen therapy is absolutely contraindicated in women at high risk of such complications (",
"    <a class=\"graphic graphic_table graphicRef59759 \" href=\"UTD.htm?1/6/1132\">",
"     table 5",
"    </a>",
"    ), including a current or a personal history of (this list is not comprehensive):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      VTE",
"     </li>",
"     <li>",
"      Inherited thrombophilia (eg, Factor V Leiden mutation, Prothrombin gene mutation)",
"     </li>",
"     <li>",
"      Myocardial infarction",
"     </li>",
"     <li>",
"      Cerebrovascular accident",
"     </li>",
"     <li>",
"      Malignancy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Risks of estrogen therapy and causes of venous thrombosis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link\">",
"     \"Overview of the causes of venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some women with contraindications to estrogen therapy (eg, hypertension) can be safely treated with estrogen for a short period (ie, &le;4 weeks), including those with the following conditions who have no vascular or thrombotic complications (this list is not comprehensive):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Diabetes",
"     </li>",
"     <li>",
"      Systemic lupus erythematosus",
"     </li>",
"     <li>",
"      Smoking",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For women in whom it is uncertain whether short-term estrogen therapy is safe, their primary care clinician should be consulted. Before initiating therapy, all women with risk factors for thrombosis should be counseled about the risks of estrogen therapy and instructed regarding warning signs of potential thrombotic events (eg, asymmetric swelling of an extremity, chest pain, shortness of breath). These women should be monitored at least weekly for these symptoms by the prescribing clinician.",
"   </p>",
"   <p>",
"    Large epidemiologic studies have not identified an increased risk of stroke, myocardial infarction, or venous thromboembolism with use of progestin-only contraceptives. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9031?source=see_link&amp;anchor=H12#H12\">",
"     \"Progestin-only pills (minipills) for contraception\", section on 'Effect on cardiovascular risk'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34522?source=see_link&amp;anchor=H17#H17\">",
"     \"Depot medroxyprogesterone acetate for contraception\", section on 'Cardiovascular risk'",
"    </a>",
"    .) However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"     norethindrone acetate",
"    </a>",
"    can be converted in the body to ethinyl estradiol, so use of this progestin should be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11305/abstract/33\">",
"     33",
"    </a>",
"    ]. The risk of thrombotic events with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    is controversial (see",
"    <a class=\"local\" href=\"#H27\">",
"     'Tranexamic acid'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Women who are not candidates for hormonal or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    therapy are treated surgically (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Uterine curettage'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H21\">",
"     'Uterine artery embolization'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H28\">",
"     'Endometrial ablation'",
"    </a>",
"    above). Women who are on anticoagulant therapy require appropriate perioperative management of these medications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link\">",
"     \"Management of anticoagulation before and after elective surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/25/14738?source=see_link\">",
"       \"Patient information: Heavy periods (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/35/23094?source=see_link\">",
"       \"Patient information: Menorrhagia (excessive menstrual bleeding) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute uterine bleeding is excessively heavy or prolonged bleeding of uterine origin sufficient in volume to require urgent or emergent intervention. Prolonged uterine bleeding is bleeding for longer than seven days. Evaluation and management of such episodes must be expedited to establish the source of bleeding and prevent or treat excessive blood loss. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goals of evaluation of women who present with profuse bleeding from the vagina are to establish hemodynamic instability, exclude pregnancy, identify the source of bleeding, and evaluate whether the bleeding requires medical",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      surgical treatment. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endometrial sampling is performed in all patients who have an episode of profuse uterine bleeding to exclude endometrial neoplasia or endometritis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Sample the endometrium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial steps to address acute or prolonged uterine bleeding in a hemodynamically unstable woman are fluid resuscitation and blood product replacement along with intrauterine tamponade. Tamponade can be accomplished using either an intrauterine balloon or gauze packing. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Intrauterine tamponade'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For hemodynamically unstable women with acute or prolonged uterine bleeding:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      As first line therapy, we suggest uterine curettage rather than medical therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Uterine curettage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For treatment of persistent bleeding after curettage or prevention of recurrent bleeding, we suggest intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/23/35184?source=see_link\">",
"       conjugated equine estrogens",
"      </a>",
"      alone rather than other medical or surgical therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Uterine curettage'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'High dose intravenous estrogen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Uterine artery embolization as a first line therapy is reserved for women in whom the etiology of bleeding is a uterine arteriovenous malformation. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Uterine artery embolization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hysterectomy is reserved for women in whom all other treatments are unsuccessful. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Hysterectomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For hemodynamically stable women with acute or prolonged uterine bleeding:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest high dose oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/23/35184?source=see_link\">",
"       conjugated equine estrogens",
"      </a>",
"      alone rather than treatment with combined estrogen-progestins, progestins, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"       tranexamic acid",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Reasonable alternatives include: progestin therapy for women with anovulatory bleeding and a thickened endometrium or combined estrogen-progestin therapy for those who prefer such treatment and are aware that it may take longer to be effective. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'High dose oral estrogen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Estrogen therapy is contraindicated in women at a high risk of thrombosis. In these women, we suggest treatment with progestins or surgery over",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"       tranexamic acid",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Women at risk of thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who are treated surgically, we suggest endometrial ablation over uterine curettage or uterine artery embolization (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For women who wish to preserve fertility, we suggest uterine curettage over uterine artery embolization (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Endometrial ablation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11305/abstract/1\">",
"      Munro MG, Mainor N, Basu R, et al. Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: a randomized controlled trial. Obstet Gynecol 2006; 108:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11305/abstract/2\">",
"      Mansfield PK, Voda A, Allison G. Validating a pencil-and-paper measure of perimenopausal menstrual blood loss. Womens Health Issues 2004; 14:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11305/abstract/3\">",
"      Medical devices; labeling for menstrual tampon for the \"ultra\" absorbency. Food and Drug Administration, HHS. Final rule. Fed Regist 2000; 65:62282.",
"     </a>",
"    </li>",
"    <li>",
"     Rhoades, R, Bell, D. Medical Physiology: Principles for clinical medicine, Lippincott Williams &amp; Wilkins, Philadelphia 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11305/abstract/5\">",
"      Grimes DA. Estimating vaginal blood loss. J Reprod Med 1979; 22:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11305/abstract/6\">",
"      Cole SK, Billewicz WZ, Thomson AM. Sources of variation in menstrual blood loss. J Obstet Gynaecol Br Commonw 1971; 78:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11305/abstract/7\">",
"      Hallberg L, H&ouml;gdahl AM, Nilsson L, Rybo G. Menstrual blood loss--a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand 1966; 45:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11305/abstract/8\">",
"      Fraser IS, McCarron G, Markham R, Resta T. Blood and total fluid content of menstrual discharge. Obstet Gynecol 1985; 65:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11305/abstract/9\">",
"      Levin RJ, Wagner G. Absorption of menstrual discharge by tampons inserted during menstruation: quantitative assessment of blood and total fluid content. Br J Obstet Gynaecol 1986; 93:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11305/abstract/10\">",
"      Fraser IS, Critchley HO, Munro MG, et al. A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding. Fertil Steril 2007; 87:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11305/abstract/11\">",
"      March CM. Bleeding problems and treatment. Clin Obstet Gynecol 1998; 41:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11305/abstract/12\">",
"      Haynes PJ, Hodgson H, Anderson AB, Turnbull AC. Measurement of menstrual blood loss in patients complaining of menorrhagia. Br J Obstet Gynaecol 1977; 84:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11305/abstract/13\">",
"      DeVore GR, Owens O, Kase N. Use of intravenous Premarin in the treatment of dysfunctional uterine bleeding--a double-blind randomized control study. Obstet Gynecol 1982; 59:285.",
"     </a>",
"    </li>",
"    <li>",
"     Speroff, L, Fritz, M. Postmenopausal hormone therapy. In: Clinical Gynecologic Endocrinology and Infertility, 7th ed, Speroff, L, Fritz, M, Lippincott Williams &amp; Wilkins, Baltimore, Maryland 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11305/abstract/15\">",
"      Zreik TG, Odunsi K, Cass I, et al. A case of fatal pulmonary thromboembolism associated with the use of intravenous estrogen therapy. Fertil Steril 1999; 71:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11305/abstract/16\">",
"      Shwayder JM. Pathophysiology of abnormal uterine bleeding. Obstet Gynecol Clin North Am 2000; 27:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11305/abstract/17\">",
"      Bayer SR, DeCherney AH. Clinical manifestations and treatment of dysfunctional uterine bleeding. JAMA 1993; 269:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11305/abstract/18\">",
"      Aksu F, Madazli R, Budak E, et al. High-dose medroxyprogesterone acetate for the treatment of dysfunctional uterine bleeding in 24 adolescents. Aust N Z J Obstet Gynaecol 1997; 37:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11305/abstract/19\">",
"      Preston JT, Cameron IT, Adams EJ, Smith SK. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol 1995; 102:401.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm190551.htm (Accessed February 1, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11305/abstract/21\">",
"      Sundstr&ouml;m A, Seaman H, Kieler H, Alfredsson L. The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research Database. BJOG 2009; 116:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11305/abstract/22\">",
"      Taparia M, Cordingley FT, Leahy MF. Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia. Eur J Haematol 2002; 68:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11305/abstract/23\">",
"      Winkler UH. The effect of tranexamic acid on the quality of life of women with heavy menstrual bleeding. Eur J Obstet Gynecol Reprod Biol 2001; 99:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11305/abstract/24\">",
"      Wellington K, Wagstaff AJ. Tranexamic acid: a review of its use in the management of menorrhagia. Drugs 2003; 63:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11305/abstract/25\">",
"      Berntorp E, Follrud C, Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost 2001; 86:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11305/abstract/26\">",
"      Iacobellis G, Iacobellis G. Combined treatment with tranexamic acid and oral contraceptive pill causes coronary ulcerated plaque and acute myocardial infarction. Cardiovasc Drugs Ther 2004; 18:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11305/abstract/27\">",
"      Fraser IS, Porte RJ, Kouides PA, Lukes AS. A benefit-risk review of systemic haemostatic agents: part 2: in excessive or heavy menstrual bleeding. Drug Saf 2008; 31:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11305/abstract/28\">",
"      Franchini M, Cianferoni L. Emergency endometrial resection in women with acute, severe uterine bleeding. J Am Assoc Gynecol Laparosc 2000; 7:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11305/abstract/29\">",
"      Milad MP, Valle RF. Emergency endometrial ablation for life-threatening uterine bleeding as a result of a coagulopathy. J Am Assoc Gynecol Laparosc 1998; 5:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11305/abstract/30\">",
"      Nichols CM, Gill EJ. Thermal balloon endometrial ablation for management of acute uterine hemorrhage. Obstet Gynecol 2002; 100:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11305/abstract/31\">",
"      Osuga Y, Okagaki R, Ozaki S, et al. Successful emergency endometrial ablation for intractable uterine bleeding in a postmenopausal woman complicated with liver cirrhosis and morbid obesity. Surg Endosc 2001; 15:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11305/abstract/32\">",
"      Richards SR. Endometrial ablation for life-threatening abnormal uterine bleeding. A report of two cases. J Reprod Med 1994; 39:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11305/abstract/33\">",
"      Chu MC, Zhang X, Gentzschein E, et al. Formation of ethinyl estradiol in women during treatment with norethindrone acetate. J Clin Endocrinol Metab 2007; 92:2205.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5415 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-E13A3EE944-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_2_11305=[""].join("\n");
var outline_f11_2_11305=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Assess hemodynamic stability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Evaluate for anemia and coagulopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Confirm uterine source and assess volume of bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Identify structural abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Sample the endometrium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      APPROACH TO MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      HEMODYNAMICALLY UNSTABLE WOMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Stabilizing the patient",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Fluid resuscitation and blood product replacement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Intrauterine tamponade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Therapeutic measures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Uterine curettage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - High dose intravenous estrogen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Uterine artery embolization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      HEMODYNAMICALLY STABLE WOMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      High dose oral estrogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      High dose oral contraceptives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      High dose progestins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Tranexamic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Endometrial ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      WOMEN AT RISK OF THROMBOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5415\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5415|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/8/44164\" title=\"figure 1\">",
"      Bakri balloon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5415|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/2/14379\" title=\"table 1\">",
"      Assessing menstrual blood loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/45/26334\" title=\"table 2\">",
"      Causes genital tract bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/52/20300\" title=\"table 3\">",
"      RBC transfusion guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/38/13932\" title=\"table 4\">",
"      Use of plasma components",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/6/1132\" title=\"table 5\">",
"      Causes of venous thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/46/32490?source=related_link\">",
"      Abdominal hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=related_link\">",
"      An overview of endometrial ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20920?source=related_link\">",
"      Approach to vaginal bleeding in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=related_link\">",
"      Chronic menorrhagia or anovulatory uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34522?source=related_link\">",
"      Depot medroxyprogesterone acetate for contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/41/35480?source=related_link\">",
"      Dilation and curettage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/8/131?source=related_link\">",
"      Endometrial sampling procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/25/20887?source=related_link\">",
"      Initial approach to the premenopausal woman with abnormal uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30408?source=related_link\">",
"      Interventional radiology in management of gynecological disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=related_link\">",
"      Management of anticoagulation before and after elective surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41929?source=related_link\">",
"      Management of postpartum hemorrhage at vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/18/35113?source=related_link\">",
"      Overview of causes of genital tract bleeding in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15465?source=related_link\">",
"      Overview of the etiology and evaluation of vaginal bleeding in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8073?source=related_link\">",
"      Pathogenesis and etiology of disseminated intravascular coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/25/14738?source=related_link\">",
"      Patient information: Heavy periods (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/35/23094?source=related_link\">",
"      Patient information: Menorrhagia (excessive menstrual bleeding) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2711?source=related_link\">",
"      Postmenopausal uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9031?source=related_link\">",
"      Progestin-only pills (minipills) for contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23944?source=related_link\">",
"      Terminology and evaluation of abnormal uterine bleeding in premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=related_link\">",
"      Treatment of anemia due to iron deficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_2_11306="Abnormal labor: Protraction and arrest disorders";
var content_f11_2_11306=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Abnormal labor: Protraction and arrest disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/2/11306/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/2/11306/contributors\">",
"     Robert M Ehsanipoor, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/2/11306/contributors\">",
"     Andrew J Satin, MD, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/2/11306/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/2/11306/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/2/11306/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/2/11306/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/2/11306/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Labor refers to uterine contractions resulting in progressive dilation and effacement of the cervix, accompanied by descent and expulsion of the fetus. Abnormal labor, dystocia, and failure to progress are imprecise terms that are used to describe a labor pattern which deviates from that observed in the majority of women who have spontaneous vaginal deliveries. More useful terminology is to characterize labor abnormalities as protraction disorders (ie, slower than normal progress) or arrest disorders (ie, complete cessation of progress).",
"   </p>",
"   <p>",
"    These disorders are the most common indication for primary cesarean delivery. In one study of 733 women who had unplanned cesareans, 68 percent of the deliveries were due to lack of progress in labor [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7768757\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protraction and arrest disorders are common. Reported incidences vary among studies due to differences in the author&rsquo;s definition of dystocia, as well as differences among study populations (eg, gestational age range, personal characteristics). About 20 percent of all labors ending in a live birth involve a protraction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    arrest disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/2\">",
"     2",
"    </a>",
"    ]. The risk is highest in nulliparous women with term pregnancies. As an example, a prospective Danish study in low risk nulliparas at term reported an incidence of 37 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL LABOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessing whether labor is progressing normally is a key component of intrapartum care; however, determining the onset of labor, measuring its progress, and evaluating the factors that affect its course (power, passenger, pelvis) is an inexact science.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30701237\">",
"    <span class=\"h2\">",
"     Definitions",
"    </span>",
"   </p>",
"   <p>",
"    There are three stages of labor:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First stage &mdash; Time from onset of contractions to complete cervical dilation. However, the precise time of onset of contractions is difficult to determine since the uterus normally contracts irregularly.",
"     </li>",
"     <li>",
"      Second stage &mdash; Time from complete cervical dilation to expulsion of the fetus.",
"     </li>",
"     <li>",
"      Third stage &mdash; Time from expulsion of the fetus to expulsion of the placenta.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first stage of labor has traditionally been divided into two phases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Latent phase &mdash; The onset of labor begins when the mother perceives regular contractions, which are typically mild and infrequent. The accompanying change in cervical dilation and effacement is gradual, less than 1 cm dilation over a single hour. The concept of a latent phase of labor is controversial, as it can be difficult to precisely determine the time of onset of contractions and the time of transition to active phase.",
"     </li>",
"     <li>",
"      Active phase &mdash; The active phase is characterized by painful contractions of increasing frequency, intensity, and duration accompanied by more rapid cervical change (at least 1",
"      <span class=\"nowrap\">",
"       cm/hour),",
"      </span>",
"      which accelerates as the active phase progresses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30701004\">",
"    <span class=\"h2\">",
"     Friedman's data",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the mid-1950s, Emanuel Friedman conducted his now classic studies attempting to define the spectrum of normal labor [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. He evaluated the course of labor of 500 primigravidas admitted to the Sloane Hospital for Women in New York. The Friedman curve and the norms established from his data have historically been widely accepted as the standard for assessment of normal labor progression.",
"   </p>",
"   <p>",
"    Friedman divided labor into a first and second stage. The first stage of labor was further divided into the latent phase, acceleration phase, phase of maximum slope, and a deceleration phase (",
"    <a class=\"graphic graphic_figure graphicRef53413 \" href=\"UTD.htm?40/54/41837\">",
"     figure 1",
"    </a>",
"    ). Based on his data, the transition from the latent phase to the acceleration phase appeared to occur at 3 to 4 cm cervical dilation and the minimum rate of acceptable cervical dilation during the active phase of labor was 1.2",
"    <span class=\"nowrap\">",
"     cm/hour",
"    </span>",
"    for nulliparous patients and 1.5",
"    <span class=\"nowrap\">",
"     cm/hour",
"    </span>",
"    for multiparous patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The applicability of the Friedman curve and its established norms to contemporary obstetric practice has recently been challenged. Several studies have evaluated labor curves and tried to establish contemporary thresholds for normal labor progression [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. The new thresholds are somewhat different from those cited by Friedman for several reasons. Clearly, there have been significant changes in patient characteristics, anesthesia practices, and obstetric practices over the past half century. In addition, a limitation of Friedman&rsquo;s findings is that his data are based on labors in only 500 women who were managed at a single institution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30701062\">",
"    <span class=\"h2\">",
"     Friedman versus contemporary data",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7768792\">",
"    <span class=\"h3\">",
"     Labor curve",
"    </span>",
"    &nbsp;&mdash;&nbsp;Zhang and colleagues determined normal labor patterns by evaluating contemporary data from the Consortium on Safe Labor, which included information on 62,415 singleton cephalic vaginal deliveries with spontaneous onset of labor and normal neonatal outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/8\">",
"     8",
"    </a>",
"    ]. The data were collected retrospectively from the electronic medical records at 19 medical centers in the United States.",
"   </p>",
"   <p>",
"    The shape of the labor curve generated from Zhang&rsquo;s data (",
"    <a class=\"graphic graphic_figure graphicRef57428 \" href=\"UTD.htm?2/20/2382\">",
"     figure 2",
"    </a>",
"    ) is different from Friedman&rsquo;s (",
"    <a class=\"graphic graphic_figure graphicRef53413 \" href=\"UTD.htm?40/54/41837\">",
"     figure 1",
"    </a>",
"    ). The Friedman curve depicts a relatively slow rate of cervical dilation until approximately 4 cm (ie, latent labor), which is followed by an abrupt acceleration in the rate of dilation until a deceleration phase at approximately 9 cm. Zhang&rsquo;s curves also demonstrate an increase in the rate of cervical dilation as labor progresses, but the increase appears to be more gradual, and greater than 50 percent of patients do not dilate at a rate of &gt;1",
"    <span class=\"nowrap\">",
"     cm/hour",
"    </span>",
"    until 5 to 6 cm dilation. They did not observe a deceleration phase at the end of the first stage of labor.",
"   </p>",
"   <p>",
"    Labor curves have been constructed from other data sets, as well, and the shapes of these curves are generally different from Friedman&rsquo;s curve [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/7,9,10\">",
"     7,9,10",
"    </a>",
"    ]. Specifically, there does not appear to be an abrupt change in the rate of cervical dilation indicating a clear transition from latent to active labor and there also does not appear to be a deceleration phase at the end of the first stage of labor. While the presence of a deceleration phase is not of major clinical significance, defining a point in labor at which rapid cervical change is expected (active labor) is clinically relevant.",
"   </p>",
"   <p>",
"    Other authors&rsquo; contemporary data also suggest that the rate of cervical change between 3 and 6 cm is likely much slower than previously thought [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/9,11\">",
"     9,11",
"    </a>",
"    ]. It is common for women who go on to have normal labors and deliveries to have rates of cervical dilation that are less than 1 cm per hour prior to 5 to 6 cm (",
"    <a class=\"graphic graphic_table graphicRef69170 \" href=\"UTD.htm?16/61/17372\">",
"     table 1",
"    </a>",
"    ). Both nulliparas and multiparas may take more than six hours to dilate from 4 to 5 cm and more than three hours to dilate from 5 to 6 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/8\">",
"     8",
"    </a>",
"    ]. However, beyond a dilation of 6 cm, rates of cervical dilation are more rapid for multiparous women.",
"   </p>",
"   <p>",
"    The time to progress 1 cm dilation in latent phase (less than 6 cm) is significantly longer in women being induced compared with those in spontaneous labor, and can take several hours [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/12\">",
"     12",
"    </a>",
"    ]. In one study, the median (95",
"    <sup>",
"     th",
"    </sup>",
"    percentile) for nulliparous women being induced to dilate from 3 to 4 cm was 1.4 hours (8.1 hours), from 4 to 5 cm, the corresponding values were 1.3 hours (6.8 hours), and from 5 to 6 cm, the values were 0.6 hours (4.3 hours). For spontaneous labor, the values were 3 to 4 cm: 0.4 hours (2.3 hours), 4 to 5 cm: 0.5 hours (2.7 hours), and 5 to 6 cm: 0.4 hours (2.7 hours), respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30701649\">",
"    <span class=\"h3\">",
"     Duration of the latent phase and the first stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, the concept of a latent phase of labor is controversial, as it can be difficult to pinpoint both the time of onset of contractions and the transition to the active phase. For these reasons, the duration of the latent phase and the first stage of labor are also difficult to determine.",
"   </p>",
"   <p>",
"    A study that compared the length of the first stage of labor (4 to 10 cm) in over 39,000 women in the Collaborative Perinatal Project (delivering 1959-1966) with that in over 98,000 women in the Consortium on Safe Labor (delivering 2002-2008) noted that the first stage of spontaneous term labor was longer in the contemporary cohort by a median 2.6 hours in nulliparas and 2.0 hours in multiparas [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/13\">",
"     13",
"    </a>",
"    ]. The differences persisted when adjusted for maternal and pregnancy characteristics, suggesting that changes in practice patterns may be the primary reason for the observation. Although epidural use has increased dramatically, it did not fully account for the difference. Despite limitations to these data, the length of the first stage seems to be increasing and merits further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30701139\">",
"    <span class=\"h3\">",
"     Duration of the active phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to Friedman, the mean (95",
"    <sup>",
"     th",
"    </sup>",
"    percentile) duration of the active phase in nulliparous and parous women was 4.6 hours (11.7) and 2.4 hours (5.2), respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most contemporary studies suggest that the upper limit of a normal active phase is longer [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/7,10,14-16\">",
"     7,10,14-16",
"    </a>",
"    ]. Zhang found that the median (95",
"    <sup>",
"     th",
"    </sup>",
"    percentile) time for the cervix to dilate from 4 to 10 cm in nulliparas and multiparas was 5.3 hours (16.4) and 3.8 hours (15.7), respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective cohort study, the duration of the first stage (defined as from 4 to 10 cm) was significantly longer in induced labor than in spontaneous labor: median (95",
"    <sup>",
"     th",
"    </sup>",
"    percentile) for induced versus spontaneous labor nulliparas 5.5 hours (16.8 hours) versus 3.8 hours (11.8 hours), respectively; multiparas 4.4 hours (16.2 hours) versus 2.4 hours (8.8 hours), respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/12\">",
"     12",
"    </a>",
"    ]. The length of the active phase (defined as from 6 to 10 cm) was short (approximately one hour) and similar in both induced and spontaneous labors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Duration of the second stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type of analgesia, duration of the first stage, parity, maternal habitus, birth weight, and station at complete dilation all play a role in predicting the duration of the second stage [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/17\">",
"     17",
"    </a>",
"    ]. For this reason, the American College of Obstetricians and Gynecologists (ACOG) recommends that the normal duration of second stage of labor be based upon parity and presence of regional anesthesia, with no intervention as long as the fetal heart rate pattern is normal and some degree of progress is observed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/18\">",
"     18",
"    </a>",
"    ]. Induction does not affect the duration of the second stage of labor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=see_link&amp;anchor=H30#H30\">",
"     \"Principles of labor induction\", section on 'Failed induction'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Friedman defined an abnormally long second stage for nulliparas and multiparas as three hours and one hour, respectively. This conclusion was derived when many of the variables described above (eg, maternal habitus, type and use of analgesia) were different from those in contemporary practice.",
"   </p>",
"   <p>",
"    Zhang found that the median (95",
"    <sup>",
"     th",
"    </sup>",
"    percentile) duration of the second stage in nulliparous and parous women with epidural anesthesia was 1.1 hours (3.6) and 0.4 hours (2.0), respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/8\">",
"     8",
"    </a>",
"    ]. Without epidural anesthesia, the median (95",
"    <sup>",
"     th",
"    </sup>",
"    percentile) was 0.6 hours (2.8) and 0.2 hours (1.3), respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF LABOR ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;One practical system for diagnosing labor abnormalities is to classify them as either protracted or arrested labor. Protraction and arrest can occur anytime during labor. The thresholds are defined according to the phase or stage of labor when they occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9307316\">",
"    <span class=\"h2\">",
"     Active phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, Friedman considered the minimum rate of acceptable cervical dilation during the active phase of labor to be 1.2",
"    <span class=\"nowrap\">",
"     cm/hour",
"    </span>",
"    for nulliparous patients and 1.5",
"    <span class=\"nowrap\">",
"     cm/hour",
"    </span>",
"    for multiparous patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/6\">",
"     6",
"    </a>",
"    ]. A slower rate of cervical dilation was diagnostic of protracted labor. A difficulty with this system is the inability to accurately define when a patient enters active labor.",
"   </p>",
"   <p>",
"    The following table serves as a better guide for determining whether labor progress is within the normal range or protracted (",
"    <a class=\"graphic graphic_table graphicRef69170 \" href=\"UTD.htm?16/61/17372\">",
"     table 1",
"    </a>",
"    ). It is based on Zhang&rsquo;s studies showing that rates of dilation in the first stage slower than those shown in the table are suggestive of a protraction disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/8\">",
"     8",
"    </a>",
"    ]. These studies demonstrated that labor may take more than six hours to progress from 4 to 5 cm and more than three hours to progress from 5 to 6 cm, regardless of parity. Labor accelerates much faster after 6 cm, and is significantly faster in multiparas compared to nulliparas at this dilation.",
"   </p>",
"   <p>",
"    An arrest disorder has traditionally been defined as a cervix that ceases to dilate after reaching &ge;4 cm dilation despite adequate uterine contractions (greater than or equal to 200 Montevideo units for two or more hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/18\">",
"     18",
"    </a>",
"    ]. Zhang&rsquo;s studies suggest that it is more reasonable to wait until cervical dilation ceases after reaching 5 to 6 cm dilation before establishing the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on these data, a workshop convened by the United States National Institute of Child Health and Human Development (NICHD), Society of Maternal-Fetal Medicine (SMFM), and ACOG proposed that first stage arrest of labor be defined as [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cervical dilation &ge;6 cm dilation and ruptured membranes with:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      No cervical change for &ge;4 hours despite adequate contractions",
"     </li>",
"     <li>",
"      No cervical change for &ge;6 hours with inadequate contractions",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9307323\">",
"    <span class=\"h2\">",
"     Second stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the second stage of labor, protracted labor has traditionally been defined as a second stage longer than two hours in nulliparas (three hours when regional analgesia is used), and longer than one hour in multiparas (two hours when regional analgesia is used) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Zhang&rsquo;s studies suggest that many women will have successful vaginal deliveries with second stages longer than these times (",
"    <a class=\"graphic graphic_table graphicRef69170 \" href=\"UTD.htm?16/61/17372\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/8\">",
"     8",
"    </a>",
"    ], thus intervention is not necessarily indicated as long as labor appears to be progressing and the fetal heart rate pattern is reassuring. Based on these data, a workshop convened by the NICHD, SMFM, and ACOG proposed that second stage arrest of labor be defined as [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No progress (descent or rotation)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Nulliparous women: &ge;4 hours with epidural anesthesia and &ge;3 hours without epidural anesthesia",
"     </li>",
"     <li>",
"      Multiparous women: &ge;3 hours with epidural anesthesia and &ge;2 hours without epidural anesthesia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1329043246\">",
"    <span class=\"h2\">",
"     Precipitous labor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of note, labor can be abnormally fast, as well as slow. The term precipitate or precipitous labor has been defined as a labor that lasts no more than three hours from onset of contractions to delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7769221\">",
"    <span class=\"h2\">",
"     Partogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of labor includes several components: a disciplined approach to the diagnosis of labor, assessment of maternal and fetal well-being, and careful monitoring of labor progress. Once active labor is diagnosed, serial cervical examinations are performed to determine whether progression is adequate [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/6\">",
"     6",
"    </a>",
"    ]. The results can be noted on a partogram, which is a graphical representation that clearly shows the patient's labor in comparison to the expected lower limit of \"normal progress.\" The partogram shows the slowest 95",
"    <sup>",
"     th",
"    </sup>",
"    percentile in labor progress based on dilation at the time of admission (",
"    <a class=\"graphic graphic_figure graphicRef81637 \" href=\"UTD.htm?11/16/11534\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/8\">",
"     8",
"    </a>",
"    ]. Deviation from this curve is diagnostic of a protraction or arrest disorder. Although useful for visualizing labor progress, use of partograms has not been proven to significantly improve obstetric outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal labor can be the result of one or more factors relating to the cervix, uterus, maternal pelvis, or fetus (ie, power, passenger, or pelvis). As an example, women with very long cervices in mid-pregnancy are more likely to experience poor progress during labor and deliver by cesarean, which suggests that cervical changes in preparation for successful vaginal delivery begin as early as the second trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/21\">",
"     21",
"    </a>",
"    ]. Interestingly, a genetic component has been purported to account for 28 percent of the susceptibility to prolonged and difficult labor [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/22\">",
"     22",
"    </a>",
"    ]. Risk factors for abnormal labor are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef66586 \" href=\"UTD.htm?12/42/12971\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/18,23\">",
"     18,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hypocontractile uterine activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypocontractile uterine activity is the most common cause of protraction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    arrest disorders in the first stage of labor. This entity refers to uterine activity that is either not sufficiently strong or not appropriately coordinated to dilate the cervix and expel the fetus. It occurs in 3 to 8 percent of parturients and has been defined as uterine contraction pressures less than 200 Montevideo units.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7769114\">",
"    <span class=\"h3\">",
"     Normal uterine activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine activity can be monitored by palpation, external tocodynamometry, or internal uterine pressure catheters. External and intrauterine monitoring devices appear to perform equally well, although the latter may work better in obese women [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ninety-five percent of women in active labor will have three to five contractions per 10 minutes. Although numerous methods for quantifying uterine activity have been reported, Montevideo units (ie, the peak strength of contractions in mmHg measured by an internal monitor multiplied by their frequency per 10 minutes) are most often employed. In a retrospective report, 91 percent of women in spontaneous active labor achieved contractile activity greater than 200 Montevideo units and 40 percent reached 300 Montevideo units [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28076832\">",
"    <span class=\"h2\">",
"     Cephalopelvic disproportion (CPD)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A disproportion in the size of the fetus relative to the mother can result in dystocia. The term CPD was originally used to describe disparity between the size of the fetus and maternal pelvis. In contemporary practice, this diagnosis is often based upon observation of protracted or arrested labor during the active phase. In this circumstance, it is often due to fetal malposition (eg, extended or asynclitic fetal head) or malpresentation (mentum posterior, brow) rather than a true disparity between fetal size and maternal pelvic dimensions.",
"   </p>",
"   <p>",
"    Antepartum, the clinician's ability to predict maternal pelvis-fetal size discordance leading to arrest of labor requiring cesarean delivery has been disappointing. Clinical and radiologic assessment of the maternal pelvis and fetal size are inexact with poor predictive value [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intrapartum, both abnormal progress of labor and certain physical findings support the diagnosis of CPD. The soft bones and open sutures of the fetal skull allow it to change in shape (ie, mold) and thus adapt to the maternal pelvis during descent. Some overlap of the parietal and occipital bones at the lambdoid sutures and overlap of the parietal and frontal bones at the coronal sutures are common in normal labor (",
"    <a class=\"graphic graphic_figure graphicRef81518 \" href=\"UTD.htm?16/32/16898\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/27\">",
"     27",
"    </a>",
"    ]. However, protracted or arrested descent with increased molding, especially overlap of the parietal bones at the sagittal suture, is suggestive of CPD.",
"   </p>",
"   <p>",
"    Interestingly, birthweight is significantly higher (3288 g versus 3199 g), the active phase of labor is slightly longer (4.6 versus 4.0 hours), and the rate of spontaneous vaginal delivery is slightly lower (84 versus 88 percent) when the fetus is male [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Malpositions and malpresentations are discussed in detail separately. (See individual topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Neuraxial anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential impact of neuraxial anesthesia on uterine activity, fetal malposition, and, ultimately arrest disorders, has received much attention as a possible source of increasing rates of cesarean delivery and protracted labor. A Cochrane review of randomized trials concluded that neuraxial anesthesia compared to non-neuraxial anesthesia or no analgesia is not associated with a significant increase in duration of the first stage of labor (weighted mean difference [WMD] 23.8 minutes; 95% CI -18.9 to 66.51) or cesarean delivery (RR 1.07; 95% CI 0.93-1.23) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/29\">",
"     29",
"    </a>",
"    ]. There were small but statistically significant increases in the second stage of labor (WMD 15.6 minutes; 95% CI 7.5-23.6) and use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    (RR 1.18 95% CI 1.03-1.34), but these findings are of questionable clinical significance. Women receiving neuraxial anesthesia were more likely to undergo operative vaginal delivery (RR 1.38; 95% CI 1.24 to 1.53).",
"   </p>",
"   <p>",
"    It is possible that recent changes in neuraxial technique or drugs (eg, use of narcotics or low-dose anesthetics) could affect these findings. The consequences of withdrawing the block before the second stage of labor, appropriate use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    augmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/30\">",
"     30",
"    </a>",
"    ], delayed pushing in the second stage, and timing of administration also need to be studied. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39562?source=see_link&amp;anchor=H12560398#H12560398\">",
"     \"Adverse effects of neuraxial analgesia and anesthesia for obstetrics\", section on 'Effect of neuraxial analgesia on labor and delivery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ACOG has stated that the decision to place a neuraxial anesthetic should depend upon the patient's wishes with consideration of factors, such as parity, also taken into account [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/31\">",
"     31",
"    </a>",
"    ]. In particular, women should not be required to reach an arbitrary cervical dilation, such as 4 to 5 cm, before receiving neuraxial anesthesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Bandl's ring",
"    </span>",
"    &nbsp;&mdash;&nbsp;An hourglass constriction ring of the uterus, called Bandl's ring, is a rare pregnancy complication associated with obstructed labor [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. The constriction forms between the upper contractile portion of the uterus and the lower uterine segment. It is not clear if it is the cause or the result of the associated dystocia. It may also occur between delivery of the first and second twin. Diagnosis is typically made at cesarean delivery. At the time of laparotomy, a transverse thickened muscular band can be observed separating the upper and lower segment of the uterus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Occiput posterior (OP) position",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent OP position is associated with longer duration of active labor and the second stage, as well as a higher risk of arrest of descent requiring operative delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. The length of the second stage appears to correlate with the degree of rotation away from occiput anterior (OA). Among nulliparous women under neuraxial anesthesia who began pushing at full dilation, the mean duration of the second stage for OA, occiput transverse (OT), and OP positions was 2.2, 2.5, and 3.0 hours, respectively, and the cesarean delivery rates were 3.4, 6.9, and 15.2 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/21/5462?source=see_link&amp;anchor=H2#H2\">",
"     \"Management of the fetus in occiput posterior position\", section on 'Risk factors and consequences'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28076958\">",
"    <span class=\"h2\">",
"     Maternal obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing maternal body mass index (BMI) correlates with an increasing length of the first stage of labor. In one study, for example, the median time to dilate from 4 to 10 cm in nulliparous women with BMI &lt;25",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    and &gt;40",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    was 5.4 and 7.7 hours, respectively, even after controlling for multiple confounders [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/39\">",
"     39",
"    </a>",
"    ]. The authors concluded more time should be allowed for labor progress in these patients. Maternal obesity is not independently correlated with the second stage of labor [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of protraction and arrest disorders depends on the etiology and",
"    <span class=\"nowrap\">",
"     stage/phase",
"    </span>",
"    of labor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9307513\">",
"    <span class=\"h2\">",
"     Patients with protracted latent phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some women do not transition to the active phase despite many hours of contractions. As discussed above, the concept of a latent phase of labor is controversial, as it can be difficult to precisely determine the time of onset of contractions, the time of transition to active phase, and the cervical dilation when this transition should occur. The diagnosis and management of latent phase of labor abnormalities are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9189?source=see_link\">",
"     \"Latent phase of labor\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Patients with protracted active phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of poor labor progression in the active phase is to confirm that the patient is in the active phase (cervix is at least 5 to 6 cm), administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    , and wait four hours. The evidence for this recommendation is described in the following meta-analyses and sections.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of nine randomized trials (n=1983 women) found that early initiation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      as soon as progress was slower than predefined criteria rather than conservative measures (eg, oxytocin deferred for &ge;4 hours, ambulation) appeared to modestly improve the probability of spontaneous vaginal delivery (RR 1.09. 95% CI 1.03-1.17) and reduce antibiotic use (RR 0.45. 95%CI 0.21-0.99) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/41\">",
"       41",
"      </a>",
"      ]. In these trials, oxytocin was initiated without consideration of baseline uterine activity and membrane status was the same in both groups.",
"     </li>",
"     <li>",
"      Another meta-analysis of eight randomized trials of 1338 low risk women in the first stage of labor at term compared early use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      (intervention group) versus",
"      <span class=\"nowrap\">",
"       placebo/no",
"      </span>",
"      <span class=\"nowrap\">",
"       treatment/delayed",
"      </span>",
"      use of oxytocin (control group) and found a significant two-hour reduction in the mean duration of labor with this intervention, but no difference between groups in cesarean delivery or instrumental delivery rates [",
"      <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/42\">",
"       42",
"      </a>",
"      ]. Although there was significant heterogeneity among the trials, results were consistent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Oxytocin augmentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     Oxytocin",
"    </a>",
"    is the only medication approved by the US Food and Drug Administration (FDA) for labor stimulation in the active phase. It is typically dosed to effect, as predicting a women's response to a particular dose is not possible [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/43\">",
"     43",
"    </a>",
"    ]. Numerous oxytocin protocols that vary in initial dose, incremental dose increase, and time interval between doses have been studied (",
"    <a class=\"graphic graphic_table graphicRef69023 \" href=\"UTD.htm?1/3/1084\">",
"     table 3",
"    </a>",
"    ). These oxytocin protocols may be used in both nulliparas and multiparas [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. We do not alter our management based on parity with one important exception: we do not use a high dose regimen in women with a previous cesarean [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High dose regimens have been associated with a high incidence of uterine tachysystole (&gt;5 contractions in 10 minutes, averaged over a 30-minute window). Low dose regimens were developed, in part, to avoid uterine tachysystole and are based upon the observation that it takes 40 to 60 minutes to reach steady state",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    levels in maternal serum [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/47\">",
"     47",
"    </a>",
"    ]. A systematic review of randomized trials of high versus low dose oxytocin for augmentation of women in spontaneous labor (10 trials, n = 5423 women) found that high dose oxytocin [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/48\">",
"     48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreased the cesarean delivery rate (RR 0.85, 95% CI 0.75-0.97) and increased the rate of spontaneous vaginal delivery (RR 1.07, 95% CI 1.02-1.12)",
"     </li>",
"     <li>",
"      Decreased the total duration of labor (mean difference -1.54 hours, 95% CI -2.44 to -0.64 hours)",
"     </li>",
"     <li>",
"      Increased the frequency of tachysystole (RR 1.91, 95% CI 1.49-2.45)",
"     </li>",
"     <li>",
"      Resulted in similar maternal and neonatal morbidities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another systematic review had fewer trials because it excluded those involving augmentation in the active management of labor, but came to similar conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decision to use a high versus a low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    regimen poses a risk benefit dilemma: higher dose regimens are associated with shorter labor and fewer cesareans, but more tachysystole. The value placed on each of these outcomes and the ability to respond to tachysystole may vary among labor and delivery units. Thus, either a high or low dose oxytocin regimen is acceptable. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1329043294\">",
"    <span class=\"h4\">",
"     Assessing progress after initiating oxytocin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditionally, active phase arrest has been diagnosed when slow cervical dilation is not corrected by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    therapy that achieves &ge;200 Montevideo units for two hours; cesarean delivery is often performed at this point. However, the two-hour threshold is not highly predictive that the patient will fail to deliver vaginally. Therefore, evaluating cervical change after four hours of adequate uterine contractions with oxytocin or six hours of inadequate uterine contractions with oxytocin is recommended prior to performing a cesarean delivery for arrest of dilatation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was illustrated in a prospective trial of 542 women with slow labors in which the obstetrician waited four to six hours (instead of two) before performing intervening surgically [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/44\">",
"     44",
"    </a>",
"    ]. Among women with persistent slow progress despite two hours of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    administration, vaginal deliveries occurred in 91 percent of multiparas and 74 percent of nulliparas. Among women with persistent slow progress despite four hours of oxytocin administration, vaginal deliveries occurred in 88 percent of multiparas and 56 percent of nulliparas. These findings suggested that extending the minimum period of oxytocin augmentation for active phase labor arrest from two hours to at least four hours was safe and increased the rate of vaginal delivery.",
"   </p>",
"   <p>",
"    The same investigators subsequently used a standardized protocol to manage 501 consecutive, term, spontaneously laboring women with slow progress in labor [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/50\">",
"     50",
"    </a>",
"    ]. The protocol involved administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    to achieve at least 200 Montevideo units for four hours before considering cesarean delivery. Vaginal delivery occurred in about 80 percent of nulliparous women and 95 percent of multiparous women, whether or not they were able to achieve",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    maintain the Montevideo unit goal. Mean (5th percentile) rates of cervical dilation in nulliparas and multiparas were 1.4",
"    <span class=\"nowrap\">",
"     cm/h",
"    </span>",
"    (0.5) and 1.8",
"    <span class=\"nowrap\">",
"     cm/h",
"    </span>",
"    (0.5), respectively. This study confirmed that oxytocin augmentation of a protraction disorder for at least four hours is both safe and effective for achieving vaginal delivery. It also showed that success was often possible despite levels of uterine activity and rates of cervical dilation that were below the normal range considered effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5029031\">",
"    <span class=\"h4\">",
"     Intrauterine pressure catheter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically, an intrauterine pressure catheter (IUPC) can be helpful, but is not mandatory, in diagnosis of hypocontractile uterine activity, particularly in patients in whom it is difficult to monitor contractions externally [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/18,44,50\">",
"     18,44,50",
"    </a>",
"    ]. In a large randomized trial of women undergoing induction or augmentation, there was no reduction in the rate of operative delivery (cesarean or instrumental vaginal) or improvement in perinatal outcome in women who underwent routine versus selective use of intrauterine catheters for measuring uterine activity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/52\">",
"     52",
"    </a>",
"    ]. Patients in the externally monitored group had an IUPC placed if there was no labor progress after two hours, contraction frequency was inadequate, or cesarean delivery was being considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28053?source=see_link\">",
"     \"Insertion of intrauterine pressure catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Other approaches",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Amniotomy",
"      </strong>",
"      &mdash; There is evidence from randomized trials that routine amniotomy does",
"      <strong>",
"       not",
"      </strong>",
"      accelerate spontaneous labor [",
"      <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/53\">",
"       53",
"      </a>",
"      ], but no trials have compared amniotomy with no intervention for management of women with intact membranes and established labor abnormalities.",
"     </li>",
"     <li>",
"      <strong>",
"       Prostaglandins",
"      </strong>",
"      &mdash; Prostaglandins are typically used for cervical ripening and labor induction; there are limited data on their safety and efficacy for treatment of protraction disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/54-56\">",
"       54-56",
"      </a>",
"      ]. We recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      rather than prostaglandins for treatment of protraction disorders, based on extensive experience and data attesting to its efficacy. Furthermore, to date, the limited available data do not suggest that prostaglandins are superior and are insufficient for determining the risks of their use in this setting.",
"     </li>",
"     <li>",
"      <strong>",
"       Evaluation of maternal hydration status",
"      </strong>",
"      and increased intravenous fluids, if indicated. (See",
"      <a class=\"local\" href=\"#H28077083\">",
"       'Volume replacement'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Ambulation",
"      </strong>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/57\">",
"       57",
"      </a>",
"      ] and",
"      <strong>",
"       continuous labor support",
"      </strong>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/58\">",
"       58",
"      </a>",
"      ] may increase the comfort of the parturient, but there is no evidence that they are clinically effective for treatment of established protraction or arrest disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Poor progression in the second stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prolonged second stage of labor (",
"    <a class=\"graphic graphic_table graphicRef69170 \" href=\"UTD.htm?16/61/17372\">",
"     table 1",
"    </a>",
"    ) warrants clinical reassessment of the mother, fetus, and expulsive forces. A variety of factors should be considered when determining when and how to intervene for slow descent in the second stage of labor. These factors include the degree to which macrosomia is suspected, adequacy of the pelvis, the fetal heart rate tracing, and maternal pushing efforts.",
"   </p>",
"   <p>",
"    Prompt use of an appropriate method of operative intervention is indicated for those fetuses with nonreassuring fetal heart rate tracings. An appropriate method of operative intervention is also indicated when cephalopelvic disproportion is likely because of macrosomia, malposition, or a clinically small maternal pelvis. Radiographic pelvimetry is of no value and is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13124?source=see_link\">",
"     \"Occiput transverse position\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/21/5462?source=see_link\">",
"     \"Management of the fetus in occiput posterior position\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31337?source=see_link\">",
"     \"Fetal macrosomia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/1/16408?source=see_link\">",
"     \"Timing and route of delivery in pregnancies at risk of shoulder dystocia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pregnancies with reassuring fetal heart rate patterns can be managed expectantly if progress is being made. Hypocontractile uterine activity should be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    . A prolonged second stage does not appear to be an independent risk factor for neonatal morbidity, with the possible exception of brachial plexus injury [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/18,59,60\">",
"     18,59,60",
"    </a>",
"    ]. A relationship between a prolonged second stage and shoulder dystocia has been reported, but inconsistently.",
"   </p>",
"   <p>",
"    On the other hand, a prolonged second stage has been associated with increased maternal risks (chorioamnionitis, postpartum hemorrhage, operative vaginal delivery,",
"    <span class=\"nowrap\">",
"     third/fourth",
"    </span>",
"    degree perineal lacerations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/23,60-64\">",
"     23,60-64",
"    </a>",
"    ]). For example, in one study of women with second stages less than and more than three hours, the rate of chorioamnionitis was 3.1 and 12.5 percent, respectively and uterine atony was 3.5 and 7.8 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/63\">",
"     63",
"    </a>",
"    ]. These complications may not have been the result of a prolonged second stage of labor, but rather additional consequences of the underlying cause of the labor abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/65\">",
"     65",
"    </a>",
"    ]. Although maternal morbidity increases with increasing duration of the second stage, the duration of the second stage alone does not mandate intervention by operative delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31493651\">",
"    <span class=\"h3\">",
"     Ineffective interventions",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lessening neuraxial blockade &mdash; Dense motor blocks from neuraxial analgesia may impair a woman's ability to push. For this reason, some experts have advocated turning down the neuraxial anesthetic to facilitate progress during a prolonged second stage. A meta-analysis including five randomized trials of epidurals discontinued late in labor compared with continuation of the same epidural protocol until birth concluded there is insufficient evidence to support the hypothesis that discontinuing epidural analgesia late in labor reduces the rate of instrumental delivery [",
"      <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/66\">",
"       66",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39562?source=see_link\">",
"       \"Adverse effects of neuraxial analgesia and anesthesia for obstetrics\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39562?source=see_link&amp;anchor=H12560398#H12560398\">",
"       \"Adverse effects of neuraxial analgesia and anesthesia for obstetrics\", section on 'Effect of neuraxial analgesia on labor and delivery'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no strong evidence that a change in maternal position (eg, upright posture, lateral, or hands and knees position instead of supine) is useful in treatment of second stage arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. Women should be encouraged to give birth in the position they find most comfortable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contemporary data on the outcome of protracted labor are limited, but generally show good neonatal outcomes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective cohort study of nulliparous women in spontaneous labor found that women with a prolonged first stage of labor (over 30 hours) were at increased risk of chorioamnionitis and cesarean delivery, but their infants were not at significantly increased risk of adverse outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective study including 2810 low risk nulliparous Danish women in spontaneous labor at term compared the outcomes of women with dystocia who received augmentation with the outcomes of a control group of women with no dystocia and no augmentation [",
"      <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/3\">",
"       3",
"      </a>",
"      ]. Importantly, in this report, a majority of women with dystocia (61 percent) were diagnosed in the second stage because of lack of descent over two hours (three hours with an epidural in place), or a lack of expulsion defined as no progress in the second stage for one hour despite good pushing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Compared to controls, women with dystocia and augmentation had fewer spontaneous deliveries (59 versus 92 percent), a higher rate of heavily meconium stained amniotic fluid (13 versus 8 percent), a higher rate of postpartum hemorrhage &ge;1000 mLs (4.2 versus 2.5 percent), and more infants with birth weights &ge;4000 g (19 versus 14 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no strong evidence that any intervention will prevent protracted labor. The best evidence is for the combination of early initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    and amniotomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20536516\">",
"    <span class=\"h2\">",
"     Oxytocin and amniotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with only mild delays in labor progress, a systematic review of randomized trials found that prophylactic use of both early amniotomy and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    appeared to shorten the first stage of labor compared with usual care (WMD -1.57 hours; 95% CI -2.15 to 1.00; 4 trials, 2431 women), and resulted in fewer cesarean deliveries (RR 0.87, 95% CI 0.77-0.99) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/71\">",
"     71",
"    </a>",
"    ]. There were less data for women with an established delay in labor progress; the trend toward a shortened first stage was similar (WMD -1.58, 95% -4.57 to 1.10; 2 trials, 240 women), but there was no reduction in the rate of cesarean delivery (RR 1.47, 95% CI 0.73-2.96)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Active management of labor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most randomized trials of the active management of labor approach have reported a reduction in protracted labors, but have not demonstrated a significant decrease in cesarean birth [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/72-75\">",
"     72-75",
"    </a>",
"    ]. How active management affects the course of labor and the components of this approach that are most important (strict criteria for diagnosis of labor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    initiation and dose, one-on-one labor support, early amniotomy, etc) are unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28077083\">",
"    <span class=\"h2\">",
"     Volume replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myometrial function may be suboptimal in women who are not adequately hydrated. Physiologists have shown that hydration improves skeletal muscle performance during prolonged exercise; however, the effects of hydration on smooth muscle are less clear [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. Two small randomized trials in laboring women observed that nulliparous women in labor given intravenous fluids at 250",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    had a lower frequency of prolonged labor and possibly less need for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    than those who received the traditional 125",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. Similarly, another randomized trial showed that nulliparous women receiving intravenous fluids with dextrose were less likely to have a prolonged labor and, in particular, there was a significant reduction in the second stage of labor [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Avoidance of occiput posterior",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women are often advised to perform exercises to facilitate anterior rotation of the fetus, but there is no good evidence that these maneuvers are effective. The lack of benefit was best illustrated by a large, multicenter, randomized trial that assigned 2547 women at 36 to 37 weeks of gestation to one of two exercise programs [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/81\">",
"     81",
"    </a>",
"    ]. Group 1 was told to take a daily walk and Group 2 was asked to assume a hands and knees position with slow pelvic rocking for 10 minutes twice a day until labor began. The incidence of persistent occiput posterior position at birth or before instrumental rotation was similar in both groups (about 8 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Pelvic floor muscle exercises",
"    </span>",
"    &nbsp;&mdash;&nbsp;Training the muscles of the pelvic floor may prevent some cases of prolonged second stage. One trial randomly assigned 301 healthy nulliparous women to an antepartum pelvic floor muscle training program or usual care from 20 to 36 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/82\">",
"     82",
"    </a>",
"    ]. Women in the intervention group trained with a physiotherapist for one hour per week and were encouraged to perform 8 to 12 intensive pelvic floor muscle contractions twice daily. Women in the exercise group were less likely to have a second stage over 60 minutes than controls (21 versus 34 percent), but the overall duration of the second stage was similar for both groups (40 and 45 minutes, respectively), as was the rate of instrumental delivery (15 and 17 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20536458\">",
"    <span class=\"h2\">",
"     Delayed pushing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pooled data from seven randomized trials (n = 2827 women) indicated that passive descent significantly increased a woman's chance of having a spontaneous vaginal birth, decreased her risk of having an instrument-assisted delivery, and decreased pushing time, but had no significant effect on rates of cesarean birth, laceration, or episiotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/83\">",
"     83",
"    </a>",
"    ]. This analysis was dominated by a randomized multicenter trial (n = 1862) that showed delayed pushing was an effective means of reducing difficult deliveries in nulliparous women (relative risk 0.79; 95% CI 0.66-0.95) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/2/11306/abstract/84\">",
"     84",
"    </a>",
"    ]. Delayed pushing predictably increased the duration of the second stage (by 54 minutes), and resulted in lower umbilical cord blood pH, but no difference was detected in overall neonatal morbidity. Maternal position and technique do not appear to affect the length of the second stage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33114?source=see_link&amp;anchor=H25#H25\">",
"     \"Management of normal labor and delivery\", section on 'Pushing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Friedman curve (",
"      <a class=\"graphic graphic_figure graphicRef53413 \" href=\"UTD.htm?40/54/41837\">",
"       figure 1",
"      </a>",
"      ) and the norms established from Friedman&rsquo;s data have historically been widely accepted as the standard for assessment of normal labor progression. Contemporary thresholds are somewhat different from those cited by Friedman because there have been significant changes in patient characteristics, anesthesia practices, and obstetric practices over the past half century, and Friedman&rsquo;s findings were based on labors in only 500 women who were managed at a single institution. (See",
"      <a class=\"local\" href=\"#H30701004\">",
"       'Friedman's data'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Contemporary studies do not show an abrupt change in the rate of cervical dilation indicating a clear transition from latent to active labor; over 50 percent of women do not dilate at a rate of &gt;1",
"      <span class=\"nowrap\">",
"       cm/hour",
"      </span>",
"      until 5 to 6 cm dilation. (See",
"      <a class=\"local\" href=\"#H30701062\">",
"       'Friedman versus contemporary data'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In contemporary studies of the active phase, the median (95",
"      <sup>",
"       th",
"      </sup>",
"      percentile) duration of time for the cervix to dilate from 4 to 10 cm in nulliparas and multiparas is 5.3 hours (16.4) and 3.8 hours (15.7), respectively. (See",
"      <a class=\"local\" href=\"#H30701139\">",
"       'Duration of the active phase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In contemporary studies of the second stage, the median (95",
"      <sup>",
"       th",
"      </sup>",
"      percentile) duration in nulliparous and parous women with epidural anesthesia was 1.1 hours (3.6) and 0.4 hours (2.0), respectively. Without epidural anesthesia, the median (95",
"      <sup>",
"       th",
"      </sup>",
"      percentile) was 0.6 hours (2.8) and 0.2 hours (1.3), respectively. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Duration of the second stage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The following table (",
"      <a class=\"graphic graphic_table graphicRef69170 \" href=\"UTD.htm?16/61/17372\">",
"       table 1",
"      </a>",
"      ) is a reasonable guide for determining when the progress of labor is protracted in the active phase and can be used with a partogram (",
"      <a class=\"graphic graphic_figure graphicRef81637 \" href=\"UTD.htm?11/16/11534\">",
"       figure 3",
"      </a>",
"      ). These data show that labor may take more than six hours to progress from 4 to 5 cm and more than three hours to progress from 5 to 6 cm, regardless of parity. (See",
"      <a class=\"local\" href=\"#H9307316\">",
"       'Active phase'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7769221\">",
"       'Partogram'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypocontractile uterine activity is the most common cause of protraction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      arrest disorders in the first stage of labor. This entity refers to uterine activity that is either not sufficiently strong or not appropriately coordinated to dilate the cervix and expel the fetus, and has been defined as uterine contraction pressures less than 200 Montevideo units. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Hypocontractile uterine activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with poor labor progression after reaching 5 to 6 cm dilation, we recommend administering",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ) and monitoring another four hours with adequate uterine contractions (&gt;200 Montevideo units), or six hours if unable to achieve this contraction pattern, before resorting to operative delivery. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Oxytocin augmentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Criteria for average and protracted second stage are shown in the table (",
"      <a class=\"graphic graphic_table graphicRef69170 \" href=\"UTD.htm?16/61/17372\">",
"       table 1",
"      </a>",
"      ). Intervention is not indicated as long as labor appears to be progressing and the fetal heart rate pattern is reassuring. (See",
"      <a class=\"local\" href=\"#H9307323\">",
"       'Second stage'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Poor progression in the second stage'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/1\">",
"      Gifford DS, Morton SC, Fiske M, et al. Lack of progress in labor as a reason for cesarean. Obstet Gynecol 2000; 95:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/2\">",
"      Zhu BP, Grigorescu V, Le T, et al. Labor dystocia and its association with interpregnancy interval. Am J Obstet Gynecol 2006; 195:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/3\">",
"      Kjaergaard H, Olsen J, Ottesen B, Dykes AK. Incidence and outcomes of dystocia in the active phase of labor in term nulliparous women with spontaneous labor onset. Acta Obstet Gynecol Scand 2009; 88:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/4\">",
"      FRIEDMAN E. The graphic analysis of labor. Am J Obstet Gynecol 1954; 68:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/5\">",
"      FRIEDMAN EA. Primigravid labor; a graphicostatistical analysis. Obstet Gynecol 1955; 6:567.",
"     </a>",
"    </li>",
"    <li>",
"     Friedman, EA, ed. Labor clinical evaluation and management. 2nd ed New York. Appleton-Century &ndash; Crofts, 1978.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/7\">",
"      Zhang J, Troendle J, Mikolajczyk R, et al. The natural history of the normal first stage of labor. Obstet Gynecol 2010; 115:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/8\">",
"      Zhang J, Landy HJ, Branch DW, et al. Contemporary patterns of spontaneous labor with normal neonatal outcomes. Obstet Gynecol 2010; 116:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/9\">",
"      Suzuki R, Horiuchi S, Ohtsu H. Evaluation of the labor curve in nulliparous Japanese women. Am J Obstet Gynecol 2010; 203:226.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/10\">",
"      Zhang J, Troendle JF, Yancey MK. Reassessing the labor curve in nulliparous women. Am J Obstet Gynecol 2002; 187:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/11\">",
"      Peisner DB, Rosen MG. Transition from latent to active labor. Obstet Gynecol 1986; 68:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/12\">",
"      Harper LM, Caughey AB, Odibo AO, et al. Normal progress of induced labor. Obstet Gynecol 2012; 119:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/13\">",
"      Laughon SK, Branch DW, Beaver J, Zhang J. Changes in labor patterns over 50 years. Am J Obstet Gynecol 2012; 206:419.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/14\">",
"      Albers LL. The duration of labor in healthy women. J Perinatol 1999; 19:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/15\">",
"      Kilpatrick SJ, Laros RK Jr. Characteristics of normal labor. Obstet Gynecol 1989; 74:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/16\">",
"      Neal JL, Lowe NK, Ahijevych KL, et al. \"Active labor\" duration and dilation rates among low-risk, nulliparous women with spontaneous labor onset: a systematic review. J Midwifery Womens Health 2010; 55:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/17\">",
"      Piper JM, Bolling DR, Newton ER. The second stage of labor: factors influencing duration. Am J Obstet Gynecol 1991; 165:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/18\">",
"      American College of Obstetrics and Gynecology Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin Number 49, December 2003: Dystocia and augmentation of labor. Obstet Gynecol 2003; 102:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/19\">",
"      Spong CY, Berghella V, Wenstrom KD, et al. Preventing the first cesarean delivery: summary of a joint Eunice Kennedy Shriver National Institute of Child Health and Human Development, Society for Maternal-Fetal Medicine, and American College of Obstetricians and Gynecologists Workshop. Obstet Gynecol 2012; 120:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/20\">",
"      Lavender T, Hart A, Smyth RM. Effect of partogram use on outcomes for women in spontaneous labour at term. Cochrane Database Syst Rev 2012; 8:CD005461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/21\">",
"      Smith GC, Celik E, To M, et al. Cervical length at mid-pregnancy and the risk of primary cesarean delivery. N Engl J Med 2008; 358:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/22\">",
"      Algovik M, Nilsson E, Cnattingius S, et al. Genetic influence on dystocia. Acta Obstet Gynecol Scand 2004; 83:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/23\">",
"      Myles TD, Santolaya J. Maternal and neonatal outcomes in patients with a prolonged second stage of labor. Obstet Gynecol 2003; 102:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/24\">",
"      Chua S, Kurup A, Arulkumaran S, Ratnam SS. Augmentation of labor: does internal tocography result in better obstetric outcome than external tocography? Obstet Gynecol 1990; 76:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/25\">",
"      Hauth JC, Hankins GD, Gilstrap LC 3rd, et al. Uterine contraction pressures with oxytocin induction/augmentation. Obstet Gynecol 1986; 68:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/26\">",
"      Pattinson RC. Pelvimetry for fetal cephalic presentations at term. Cochrane Database Syst Rev 2000; :CD000161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/27\">",
"      Maharaj D. Assessing cephalopelvic disproportion: back to the basics. Obstet Gynecol Surv 2010; 65:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/28\">",
"      Cahill AG, Roehl KA, Odibo AO, et al. Impact of fetal gender on the labor curve. Am J Obstet Gynecol 2012; 206:335.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/29\">",
"      Anim-Somuah M, Smyth R, Howell C. Epidural versus non-epidural or no analgesia in labour. Cochrane Database Syst Rev 2005; :CD000331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/30\">",
"      Costley PL, East CE. Oxytocin augmentation of labour in women with epidural analgesia for reducing operative deliveries. Cochrane Database Syst Rev 2012; 5:CD009241.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Obstetric analgesia and anesthesia. ACOG practice bulletin #36. Obstet Gynecol 2002; 100;177.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/32\">",
"      Turrentine MA, Andres RL. Modern analysis of pathologic uterine rings. South Med J 1997; 90:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/33\">",
"      Turrentine MA, Andres RL. Recurrent Bandl's ring as an etiology for failed vaginal birth after cesarean section. Am J Perinatol 1994; 11:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/34\">",
"      Lauria MR, Barthold JC, Zimmerman RA, Turrentine MA. Pathologic uterine ring associated with fetal head trauma and subsequent cerebral palsy. Obstet Gynecol 2007; 109:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/35\">",
"      Gardberg M, Tuppurainen M. Persistent occiput posterior presentation--a clinical problem. Acta Obstet Gynecol Scand 1994; 73:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/36\">",
"      Ponkey SE, Cohen AP, Heffner LJ, Lieberman E. Persistent fetal occiput posterior position: obstetric outcomes. Obstet Gynecol 2003; 101:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/37\">",
"      Sizer AR, Nirmal DM. Occipitoposterior position: associated factors and obstetric outcome in nulliparas. Obstet Gynecol 2000; 96:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/38\">",
"      Sen&eacute;cal J, Xiong X, Fraser WD, Pushing Early Or Pushing Late with Epidural study group. Effect of fetal position on second-stage duration and labor outcome. Obstet Gynecol 2005; 105:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/39\">",
"      Kominiarek MA, Zhang J, Vanveldhuisen P, et al. Contemporary labor patterns: the impact of maternal body mass index. Am J Obstet Gynecol 2011; 205:244.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/40\">",
"      Robinson BK, Mapp DC, Bloom SL, et al. Increasing maternal body mass index and characteristics of the second stage of labor. Obstet Gynecol 2011; 118:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/41\">",
"      Wei SQ, Luo ZC, Xu H, Fraser WD. The effect of early oxytocin augmentation in labor: a meta-analysis. Obstet Gynecol 2009; 114:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/42\">",
"      Bugg GJ, Siddiqui F, Thornton JG. Oxytocin versus no treatment or delayed treatment for slow progress in the first stage of spontaneous labour. Cochrane Database Syst Rev 2011; :CD007123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/43\">",
"      Satin AJ, Leveno KJ, Sherman ML, McIntire DD. Factors affecting the dose response to oxytocin for labor stimulation. Am J Obstet Gynecol 1992; 166:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/44\">",
"      Rouse DJ, Owen J, Hauth JC. Active-phase labor arrest: oxytocin augmentation for at least 4 hours. Obstet Gynecol 1999; 93:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/45\">",
"      Satin AJ, Leveno KJ, Sherman ML, et al. High- versus low-dose oxytocin for labor stimulation. Obstet Gynecol 1992; 80:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/46\">",
"      Satin AJ, Leveno KJ, Sherman ML, McIntire D. High-dose oxytocin: 20- versus 40-minute dosage interval. Obstet Gynecol 1994; 83:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/47\">",
"      Seitchik J, Amico J, Robinson AG, Castillo M. Oxytocin augmentation of dysfunctional labor. IV. Oxytocin pharmacokinetics. Am J Obstet Gynecol 1984; 150:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/48\">",
"      Wei SQ, Luo ZC, Qi HP, et al. High-dose vs low-dose oxytocin for labor augmentation: a systematic review. Am J Obstet Gynecol 2010; 203:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/49\">",
"      Mori R, Tokumasu H, Pledge D, Kenyon S. High dose versus low dose oxytocin for augmentation of delayed labour. Cochrane Database Syst Rev 2011; :CD007201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/50\">",
"      Rouse DJ, Owen J, Savage KG, Hauth JC. Active phase labor arrest: revisiting the 2-hour minimum. Obstet Gynecol 2001; 98:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/51\">",
"      Kenyon S, Ullman R, Mori R, Whittle M. Care of healthy women and their babies during childbirth: summary of NICE guidance. BMJ 2007; 335:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/52\">",
"      Bakker JJ, Verhoeven CJ, Janssen PF, et al. Outcomes after internal versus external tocodynamometry for monitoring labor. N Engl J Med 2010; 362:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/53\">",
"      Smyth RM, Alldred SK, Markham C. Amniotomy for shortening spontaneous labour. Cochrane Database Syst Rev 2007; :CD006167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/54\">",
"      Oppenheimer LW, Labrecque M, Wells G, et al. Prostaglandin E vaginal gel to treat dystocia in spontaneous labour: a multicentre randomised placebo-controlled trial. BJOG 2005; 112:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/55\">",
"      Bleich AT, Villano KS, Lo JY, et al. Oral misoprostol for labor augmentation: a randomized controlled trial. Obstet Gynecol 2011; 118:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/56\">",
"      Ho M, Cheng SY, Li TC. Titrated oral misoprostol solution compared with intravenous oxytocin for labor augmentation: a randomized controlled trial. Obstet Gynecol 2010; 116:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/57\">",
"      Bloom SL, McIntire DD, Kelly MA, et al. Lack of effect of walking on labor and delivery. N Engl J Med 1998; 339:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/58\">",
"      Hodnett ED, Gates S, Hofmeyr GJ, et al. Continuous support for women during childbirth. Cochrane Database Syst Rev 2011; :CD003766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/59\">",
"      Cohen WR. Influence of the duration of second stage labor on perinatal outcome and puerperal morbidity. Obstet Gynecol 1977; 49:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/60\">",
"      Cheng YW, Hopkins LM, Caughey AB. How long is too long: Does a prolonged second stage of labor in nulliparous women affect maternal and neonatal outcomes? Am J Obstet Gynecol 2004; 191:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/61\">",
"      Cheng YW, Hopkins LM, Laros RK Jr, Caughey AB. Duration of the second stage of labor in multiparous women: maternal and neonatal outcomes. Am J Obstet Gynecol 2007; 196:585.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/62\">",
"      Allen VM, Baskett TF, O'Connell CM, et al. Maternal and perinatal outcomes with increasing duration of the second stage of labor. Obstet Gynecol 2009; 113:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/63\">",
"      Rouse DJ, Weiner SJ, Bloom SL, et al. Second-stage labor duration in nulliparous women: relationship to maternal and perinatal outcomes. Am J Obstet Gynecol 2009; 201:357.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/64\">",
"      Le Ray C, Audibert F, Goffinet F, Fraser W. When to stop pushing: effects of duration of second-stage expulsion efforts on maternal and neonatal outcomes in nulliparous women with epidural analgesia. Am J Obstet Gynecol 2009; 201:361.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/65\">",
"      Caughey AB. Is there an upper time limit for the management of the second stage of labor? Am J Obstet Gynecol 2009; 201:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/66\">",
"      Torvaldsen S, Roberts CL, Bell JC, Raynes-Greenow CH. Discontinuation of epidural analgesia late in labour for reducing the adverse delivery outcomes associated with epidural analgesia. Cochrane Database Syst Rev 2004; :CD004457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/67\">",
"      Hofmeyr GJ, Kulier R. Hands/knees posture in late pregnancy or labour for fetal malposition (lateral or posterior). Cochrane Database Syst Rev 2000; :CD001063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/68\">",
"      Gupta JK, Hofmeyr GJ, Shehmar M. Position in the second stage of labour for women without epidural anaesthesia. Cochrane Database Syst Rev 2012; 5:CD002006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/69\">",
"      Roberts CL, Algert CS, Cameron CA, Torvaldsen S. A meta-analysis of upright positions in the second stage to reduce instrumental deliveries in women with epidural analgesia. Acta Obstet Gynecol Scand 2005; 84:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/70\">",
"      Cheng YW, Shaffer BL, Bryant AS, Caughey AB. Length of the first stage of labor and associated perinatal outcomes in nulliparous women. Obstet Gynecol 2010; 116:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/71\">",
"      Wei S, Wo BL, Qi HP, et al. Early amniotomy and early oxytocin for prevention of, or therapy for, delay in first stage spontaneous labour compared with routine care. Cochrane Database Syst Rev 2012; 9:CD006794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/72\">",
"      Sadler LC, Davison T, McCowan LM. A randomised controlled trial and meta-analysis of active management of labour. BJOG 2000; 107:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/73\">",
"      L&oacute;pez-Zeno JA, Peaceman AM, Adashek JA, Socol ML. A controlled trial of a program for the active management of labor. N Engl J Med 1992; 326:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/74\">",
"      Frigoletto FD Jr, Lieberman E, Lang JM, et al. A clinical trial of active management of labor. N Engl J Med 1995; 333:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/75\">",
"      Rogers R, Gilson GJ, Miller AC, et al. Active management of labor: does it make a difference? Am J Obstet Gynecol 1997; 177:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/76\">",
"      Maughan RJ, Bethell LR, Leiper JB. Effects of ingested fluids on exercise capacity and on cardiovascular and metabolic responses to prolonged exercise in man. Exp Physiol 1996; 81:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/77\">",
"      Montain SJ, Coyle EF. Influence of graded dehydration on hyperthermia and cardiovascular drift during exercise. J Appl Physiol 1992; 73:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/78\">",
"      Garite TJ, Weeks J, Peters-Phair K, et al. A randomized controlled trial of the effect of increased intravenous hydration on the course of labor in nulliparous women. Am J Obstet Gynecol 2000; 183:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/79\">",
"      Eslamian L, Marsoosi V, Pakneeyat Y. Increased intravenous fluid intake and the course of labor in nulliparous women. Int J Gynaecol Obstet 2006; 93:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/80\">",
"      Shrivastava VK, Garite TJ, Jenkins SM, et al. A randomized, double-blinded, controlled trial comparing parenteral normal saline with and without dextrose on the course of labor in nulliparas. Am J Obstet Gynecol 2009; 200:379.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/81\">",
"      Kariminia A, Chamberlain ME, Keogh J, Shea A. Randomised controlled trial of effect of hands and knees posturing on incidence of occiput posterior position at birth. BMJ 2004; 328:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/82\">",
"      Salvesen KA, M&oslash;rkved S. Randomised controlled trial of pelvic floor muscle training during pregnancy. BMJ 2004; 329:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/83\">",
"      Brancato RM, Church S, Stone PW. A meta-analysis of passive descent versus immediate pushing in nulliparous women with epidural analgesia in the second stage of labor. J Obstet Gynecol Neonatal Nurs 2008; 37:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/2/11306/abstract/84\">",
"      Fraser WD, Marcoux S, Krauss I, et al. Multicenter, randomized, controlled trial of delayed pushing for nulliparous women in the second stage of labor with continuous epidural analgesia. The PEOPLE (Pushing Early or Pushing Late with Epidural) Study Group. Am J Obstet Gynecol 2000; 182:1165.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4464 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-5A6B11C91F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_2_11306=[""].join("\n");
var outline_f11_2_11306=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7768757\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL LABOR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30701237\">",
"      Definitions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30701004\">",
"      Friedman's data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30701062\">",
"      Friedman versus contemporary data",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7768792\">",
"      - Labor curve",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30701649\">",
"      - Duration of the latent phase and the first stage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30701139\">",
"      - Duration of the active phase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Duration of the second stage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS OF LABOR ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9307316\">",
"      Active phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9307323\">",
"      Second stage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1329043246\">",
"      Precipitous labor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7769221\">",
"      Partogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ETIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hypocontractile uterine activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7769114\">",
"      - Normal uterine activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28076832\">",
"      Cephalopelvic disproportion (CPD)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Neuraxial anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Bandl's ring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Occiput posterior (OP) position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28076958\">",
"      Maternal obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9307513\">",
"      Patients with protracted latent phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Patients with protracted active phase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Oxytocin augmentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1329043294\">",
"      Assessing progress after initiating oxytocin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5029031\">",
"      Intrauterine pressure catheter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Other approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Poor progression in the second stage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31493651\">",
"      - Ineffective interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20536516\">",
"      Oxytocin and amniotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Active management of labor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28077083\">",
"      Volume replacement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Avoidance of occiput posterior",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Pelvic floor muscle exercises",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20536458\">",
"      Delayed pushing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4464\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4464|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/54/41837\" title=\"figure 1\">",
"      Labor curve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/20/2382\" title=\"figure 2\">",
"      Average labor curve by parity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/16/11534\" title=\"figure 3\">",
"      Duration of labor by dilation at admission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/32/16898\" title=\"figure 4\">",
"      Fontanelles and suture lines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4464|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/61/17372\" title=\"table 1\">",
"      Duration of labor by parity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/42/12971\" title=\"table 2\">",
"      Risk factors for dystocia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/3/1084\" title=\"table 3\">",
"      Examples of oxytocin infusion protocols",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39562?source=related_link\">",
"      Adverse effects of neuraxial analgesia and anesthesia for obstetrics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31337?source=related_link\">",
"      Fetal macrosomia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28053?source=related_link\">",
"      Insertion of intrauterine pressure catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9189?source=related_link\">",
"      Latent phase of labor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33114?source=related_link\">",
"      Management of normal labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/21/5462?source=related_link\">",
"      Management of the fetus in occiput posterior position",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13124?source=related_link\">",
"      Occiput transverse position",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=related_link\">",
"      Principles of labor induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/1/16408?source=related_link\">",
"      Timing and route of delivery in pregnancies at risk of shoulder dystocia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_2_11307="Fallop tube cancer FIGO surv";
var content_f11_2_11307=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F55344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F55344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Carcinoma of the Fallopian tube: FIGO stage and five-year survival for patients treated in 1999-2001.",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        FIGO stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of patients (n)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Five-year survival (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        81.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        II",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        66.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        41.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        33.3",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Original table modified for this publication. From: Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the fallopian tube. Int J Gynaecol Obstet 2006; 95:S145. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_2_11307=[""].join("\n");
var outline_f11_2_11307=null;
var title_f11_2_11308="Diagnostic criteria paroxysmal hemicrania";
var content_f11_2_11308=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F58505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F58505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for paroxysmal hemicrania",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        A. At least 20 attacks fulfilling B-D",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. Severe unilateral orbital, supraorbital, or temporal pain lasting 2 to 30 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        C. Headache is accompanied by at least one of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1. Ipsilateral conjunctival injection and/or lacrimation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2. Ipsilateral nasal congestion and/or rhinorrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        3. Forehead and facial sweating",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        4. Ipsilateral eyelid edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        5. Ipsilateral forehead and facial sweating",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        6. Ipsilateral miosis and/or ptosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D. Attacks have a frequency &gt;5 per day for more than half the time, although periods with lower frequency may occur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        E. Attacks are prevented completely by therapeutic doses of indomethacin*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        F. Not attributed to another disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Episodic paroxysmal headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Description: occurs in periods lasting seven days to one year separated by pain free periods lasting one month or more",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Chronic paroxysmal headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Description: attacks occur for more than one year without remission or with remissions lasting less than one month",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * To rule out an incomplete response, indomethacin should be used in a dose of &ge;150 mg daily orally or rectally, or &ge;100 mg by injection. Smaller doses are often sufficient for maintenance.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted by permission of Sage: Headache classification subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9. Copyright &copy; 2004 Sage Publications.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_2_11308=[""].join("\n");
var outline_f11_2_11308=null;
var title_f11_2_11309="Evaluation of child IBD";
var content_f11_2_11309=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation of the child with suspected inflammatory bowel disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        History",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal pain, appetite",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stool frequency, consistency, rectal bleeding, nocturnal diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Family history: relatives with inflammatory bowel disease, familial growth patterns",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Previous growth data*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        School attendance and daily activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychosocial history, including impact upon daily life of patient and parent(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Physical examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Height and weight, evaluating for trends and growth velocity*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal examination: tenderness, mass",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rectal examination: evaluate for perianal disease and occult blood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rash, arthritis, clubbing, oral lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sexual maturity staging (Tanner stage)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Laboratory tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CBC with differential count, platelets, ESR, C-reactive protein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum total protein, albumin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stool guaiac (hemoccult), leukocytes, calprotectin; urine analysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stool bacterial culture, smears for ova and parasite, C. difficile toxin assay",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tuberculosis screening (tuberculin skin test)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Additional tests as indicated, depending upon clinical findings:",
"        </p>",
"        <ul>",
"         <li>",
"          To further characterize the type of inflammatory bowel disease: P-ANCA, ASCA",
"         </li>",
"         <li>",
"          To investigate other causes of diarrhea: lactose/glucose hydrogen breath test for lactose intolerance/bacterial overgrowth, 72-hour fecal fat quantitation, and stool alpha-1-antitrypsin",
"         </li>",
"         <li>",
"          If poor nutrition is suspected: serum iron, calcium, magnesium, folate, vitamins A, E, B12, and zinc*",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Radiographic studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         For localization of small bowel disease, one of the following:",
"        </p>",
"        <ul>",
"         <li>",
"          Upper GI series with small bowel follow-through",
"         </li>",
"         <li>",
"          Abdominal MRI with oral contrast",
"         </li>",
"         <li>",
"          Abdominal CT with oral contrast",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Additional tests as indicated, depending upon clinical findings: bone age*, abdominal plain films, fistulogram, ultrasound or HMPAO-labeled white blood cell scan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Endoscopic studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colonoscopy (including ileoscopy) with biopsies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Upper endoscopy with biopsies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Additional procedures as indicated:",
"        </p>",
"        <ul>",
"         <li>",
"          Video capsule endoscopy if more information on small bowel involvement is needed",
"         </li>",
"         <li>",
"          MRCP or ERCP if sclerosing cholangitis is suspected",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CBC: complete blood count; ESR: erythrocyte sedimentation rate; P-ANCA: perinuclear antineutrophil cytoplasmic antibodies (P-ANCA); ASCA: Anti-Saccharomyces cerevisiae antibodies; MRI: magnetic resonance imaging; CT: computerized tomography; HMPAO: hexamethylpropyleneamineoxime; MRCP: magnetic resonance cholangiopancreatography; ERCP: endoscopic retrograde cholangiopancreatography.",
"     <br/>",
"     * For a more detailed discussion, refer to UpToDate topic review on growth failure in children with inflammatory bowel disease.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Shashidhar H, Integlia MJ, Grand RJ. Clinical manifestations of pediatric inflammatory bowel disease. In: Inflammatory Bowel Disease, Kirsner JB (Ed), WB Saunders, Philadelphia 2000. Copyright &copy; 2000 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_2_11309=[""].join("\n");
var outline_f11_2_11309=null;
var title_f11_2_11310="Restenosis within a saphenous vein graft";
var content_f11_2_11310=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/61140/restsaph_conv.mp4?title=Restenosis+within+a+saphenous+vein+graft\" style=\"width:160px;height:304px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Restenosis within a saphenous vein graft",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 160px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A saphenous vein bypass graft to the obtuse marginal branch of the circumflex artery is shown here. In the mid portion of the graft a long area of irregular narrowing is seen. This represents a restenosis from a previous intervention (stent placement) two months ago.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John D Carroll, MD. This type of movie will be part of The Multimedia Textbook of Coronary Arteriography and Interventions, Williams &amp; Wilkins, Baltimore, Fall 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_2_11310=[""].join("\n");
var outline_f11_2_11310=null;
var title_f11_2_11311="Giant urticaria";
var content_f11_2_11311=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Giant urticaria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 248px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Very large erythematous annular lesion of the shoulder with central clearing. This patient had several large lesions of this type which could be confused with erythema migrans.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lee T Nesbitt, Jr. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_2_11311=[""].join("\n");
var outline_f11_2_11311=null;
